6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
more	JJR	more	more	more	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Elderly	JJ	elderly	elderly	elderli	Y	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Dementia	NNP	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
Related	JJ	related	related	relat	N	O
Psychosis	NNP	psychosis	psychosis	psychosi	Y	O
[	NNP	[	[	[	N	O
seeBoxed	VBD	seeboxed	seeboxed	seebox	N	O
Warningand	NNP	warningand	warningand	warningand	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
and5	NN	and5	and5	and5	N	O
.	.	.	.	.	N	O
2	CD	2	2	2	N	O
)]	NN	)]	)]	)]	N	O

Neuroleptic	JJ	neuroleptic	neuroleptic	neurolept	N	B-AdverseReaction
Malignant	NNP	malignant	malignant	malign	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

Tardive	JJ	tardive	tardive	tardiv	N	B-AdverseReaction
Dyskinesia	NNP	dyskinesia	dyskinesia	dyskinesia	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O

Metabolic	NNP	metabolic	metabolic	metabol	N	B-AdverseReaction
Changes	NNP	changes	change	chang	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Patient	NNP	patient	patient	patient	N	O
Counseling	NNP	counseling	counseling	counsel	N	O
Information	NNP	information	information	inform	N	O
(	(	(	(	(	N	O
17	CD	17	17	17	N	O
)]	NN	)]	)]	)]	N	O

Application	NNP	application	application	applic	N	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
oral	JJ	oral	oral	oral	N	I-AdverseReaction
ulcers	NNS	ulcers	ulcer	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
blisters	NNS	blisters	blister	blister	Y	I-AdverseReaction
,	,	,	,	,	N	O
peeling	VBG	peeling	peeling	peel	Y	I-AdverseReaction
sloughing	NN	sloughing	sloughing	slough	Y	I-AdverseReaction
and	CC	and	and	and	N	O
inflammation	NN	inflammation	inflammation	inflamm	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)]	NN	)]	)]	)]	N	O

Orthostatic	JJ	orthostatic	orthostatic	orthostat	N	B-AdverseReaction
Hypotension	NNP	hypotension	hypotension	hypotens	Y	I-AdverseReaction
,	,	,	,	,	N	O
Syncope	NNP	syncope	syncope	syncop	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
Hemodynamic	NNP	hemodynamic	hemodynamic	hemodynam	N	B-AdverseReaction
Effects	NNPS	effects	effect	effect	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)]	NN	)]	)]	)]	N	O

Leukopenia	NNP	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Agranulocytosis	NNP	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)]	NN	)]	)]	)]	N	O

QT	NNP	qt	qt	qt	N	B-AdverseReaction
Interval	NNP	interval	interval	interv	N	I-AdverseReaction
Prolongation	NNP	prolongation	prolongation	prolong	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)]	NN	)]	)]	)]	N	O

Hyperprolactinemia	NNP	hyperprolactinemia	hyperprolactinemia	hyperprolactinemia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.10	CD	5.10	5.10	5.10	N	O
)]	NN	)]	)]	)]	N	O

Seizures	NNS	seizures	seizure	seizur	Y	B-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.11	CD	5.11	5.11	5.11	N	O
)]	NN	)]	)]	)]	N	O

Potential	NNP	potential	potential	potenti	N	B-Factor
for	IN	for	for	for	N	O
Cognitive	NNP	cognitive	cognitive	cognit	N	B-AdverseReaction
and	CC	and	and	and	N	O
Motor	NNP	motor	motor	motor	N	B-AdverseReaction
Impairment	NNP	impairment	impairment	impair	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.12	CD	5.12	5.12	5.12	N	O
)]	NN	)]	)]	)]	N	O

Body	NN	body	body	bodi	N	O
Temperature	NNP	temperature	temperature	temperatur	N	O
Regulation	NNP	regulation	regulation	regul	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.13	CD	5.13	5.13	5.13	N	O
)]	NN	)]	)]	)]	N	O

Suicide	NNP	suicide	suicide	suicid	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.14	CD	5.14	5.14	5.14	N	O
)]	NN	)]	)]	)]	N	O

Dysphagia	NNP	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.15	CD	5.15	5.15	5.15	N	O
)]	NN	)]	)]	)]	N	O

Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Illness	NNP	illness	illness	ill	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.16	CD	5.16	5.16	5.16	N	O
)]	NN	)]	)]	)]	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
twice	RB	twice	twice	twice	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
reported	VBD	reported	reported	report	N	O
with	IN	with	with	with	N	O
acute	JJ	acute	acute	acut	N	O
treatment	NN	treatment	treatment	treatment	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
with	IN	with	with	with	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
were	VBD	were	were	were	N	O
akathisia	RB	akathisia	akathisia	akathisia	Y	B-AdverseReaction
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
profile	NN	profile	profile	profil	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
maintenance	NN	maintenance	maintenance	mainten	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
that	DT	that	that	that	N	O
seen	VBN	seen	seen	seen	N	O
with	IN	with	with	with	N	O
acute	JJ	acute	acute	acut	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O

most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
twice	RB	twice	twice	twice	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
reported	VBD	reported	reported	report	N	O
with	IN	with	with	with	N	O
acute	JJ	acute	acute	acut	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
manic	NN	manic	manic	manic	Y	O
or	CC	or	or	or	N	O
mixed	JJ	mixed	mixed	mix	N	O
episodes	NNS	episodes	episode	episod	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
I	PRP	i	i	i	N	O
disorder	VBP	disorder	disorder	disord	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
were	VBD	were	were	were	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
extrapyramidal	NN	extrapyramidal	extrapyramidal	extrapyramid	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
other	JJ	other	other	other	N	B-Factor
than	IN	than	than	than	N	I-Factor
akathisia	NN	akathisia	akathisia	akathisia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
weight	NN	weight	weight	weight	Y	I-AdverseReaction
and	CC	and	and	and	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
therapy	NN	therapy	therapy	therapi	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
bipolar	NN	bipolar	bipolar	bipolar	N	O
I	PRP	i	i	i	N	O
disorder	VBP	disorder	disorder	disord	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
were	VBD	were	were	were	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
and	CC	and	and	and	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
adult	NN	adult	adult	adult	N	O
information	NN	information	information	inform	N	O
below	IN	below	below	below	N	O
is	VBZ	is	is	is	N	O
derived	VBN	derived	derived	deriv	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
database	NN	database	database	databas	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
consisting	NN	consisting	consisting	consist	N	O
of	IN	of	of	of	N	O
over	IN	over	over	over	N	O
4565	CD	4565	4565	4565	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
healthy	JJ	healthy	healthy	healthi	N	O
subjects	NNS	subjects	subject	subject	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
one	CD	one	one	one	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
sublingual	JJ	sublingual	sublingual	sublingu	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
1314	CD	1314	1314	1314	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
and	CC	and	and	and	N	O
785	CD	785	785	785	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
52	CD	52	52	52	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
at	IN	at	at	at	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
doses	NNS	doses	dos	dose	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
twice	RB	twice	twice	twice	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
I	PRP	i	i	i	N	O
disorder	VBP	disorder	disorder	disord	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
were	VBD	were	were	were	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysgeusia	NN	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
weight	NN	weight	weight	weight	Y	I-AdverseReaction
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
new	JJ	new	new	new	N	O
major	JJ	major	major	major	N	O
safety	NN	safety	safety	safeti	N	O
findings	NNS	findings	finding	find	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
50	CD	50	50	50	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
safety	NN	safety	safety	safeti	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
651	CD	651	651	651	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
352	CD	352	352	352	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
180	CD	180	180	180	N	O
days	NNS	days	day	day	N	O
and	CC	and	and	and	N	O
58	CD	58	58	58	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
had	VBD	had	had	had	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
year	NN	year	year	year	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
403	CD	403	403	403	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
I	PRP	i	i	i	N	O
disorder	VBP	disorder	disorder	disord	N	O
who	WP	who	who	who	N	O
participated	VBD	participated	participated	particip	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
whom	WP	whom	whom	whom	N	O
302	CD	302	302	302	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
at	IN	at	at	at	N	O
fixed	JJ	fixed	fixed	fix	N	O
doses	NNS	doses	dos	dose	N	O
ranging	VBG	ranging	ranging	rang	N	O
from	IN	from	from	from	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NNS	mg	mg	mg	N	O
to	TO	to	to	to	N	O
10	CD	10	10	10	N	O
mg	NNS	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
stated	JJ	stated	stated	state	N	O
frequencies	NNS	frequencies	frequency	frequenc	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
represent	VBP	represent	represent	repres	N	O
the	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
individuals	NNS	individuals	individual	individu	N	O
who	WP	who	who	who	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
type	NN	type	type	type	N	O
listed	VBN	listed	listed	list	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
reaction	NN	reaction	reaction	reaction	N	O
was	VBD	was	wa	wa	N	O
considered	VBN	considered	considered	consid	N	O
treatment	NN	treatment	treatment	treatment	N	O
emergent	NN	emergent	emergent	emerg	N	O
if	IN	if	if	if	N	O
it	PRP	it	it	it	N	O
occurred	VBD	occurred	occurred	occur	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
time	NN	time	time	time	N	O
or	CC	or	or	or	N	O
worsened	VBN	worsened	worsened	worsen	N	O
while	IN	while	while	while	N	O
receiving	VBG	receiving	receiving	receiv	N	O
therapy	NN	therapy	therapy	therapi	N	O
following	VBG	following	following	follow	N	O
baseline	JJ	baseline	baseline	baselin	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Commonly	RB	commonly	commonly	commonli	N	O
observed	VBD	observed	observed	observ	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
5%	CD	5%	5%	5%	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
twice	NN	twice	twice	twice	N	O
that	DT	that	that	that	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O

Schizophrenia	NNP	schizophrenia	schizophrenia	schizophrenia	Y	O
Adults	NNS	adults	adult	adult	N	O
:	:	:	:	:	N	O
akathisia	NN	akathisia	akathisia	akathisia	Y	B-AdverseReaction
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	I-AdverseReaction
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
.	.	.	.	.	N	O

Bipolar	JJ	bipolar	bipolar	bipolar	N	O
Disorder	NNP	disorder	disorder	disord	N	O
Adults	NNP	adults	adult	adult	N	O
(	(	(	(	(	N	O
Monotherapy	NNP	monotherapy	monotherapy	monotherapi	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
extrapyramidal	NN	extrapyramidal	extrapyramidal	extrapyramid	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
other	JJ	other	other	other	N	B-Factor
than	IN	than	than	than	N	I-Factor
akathisia	JJ	akathisia	akathisia	akathisia	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	JJ	increased	increased	increas	N	B-AdverseReaction
weight	NN	weight	weight	weight	Y	I-AdverseReaction
.	.	.	.	.	N	O

Bipolar	JJ	bipolar	bipolar	bipolar	N	O
Disorder	NNP	disorder	disorder	disord	N	O
Pediatric	NNP	pediatric	pediatric	pediatr	N	O
Patients	NNP	patients	patient	patient	N	O
(	(	(	(	(	N	O
Monotherapy	NNP	monotherapy	monotherapy	monotherapi	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysgeusia	NN	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
weight	NN	weight	weight	weight	Y	I-AdverseReaction
.	.	.	.	.	N	O

Bipolar	JJ	bipolar	bipolar	bipolar	N	O
Disorder	NNP	disorder	disorder	disord	N	O
Adults	NNP	adults	adult	adult	N	O
(	(	(	(	(	N	O
Adjunctive	NNP	adjunctive	adjunctive	adjunct	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	I-AdverseReaction
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Forest	NNP	forest	forest	forest	N	O
Laboratories	NNPS	laboratories	laboratory	laboratori	N	O
,	,	,	,	,	N	O
LLC	NNP	llc	llc	llc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
678	CD	678	678	678	N	O
-	:	-	-	-	N	O
1605	CD	1605	1605	1605	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Adult	NN	adult	adult	adult	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Schizophrenia	NNP	schizophrenia	schizophrenia	schizophrenia	Y	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
findings	NNS	findings	finding	find	N	O
are	VBP	are	are	are	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
trials	NNS	trials	trial	trial	N	O
for	IN	for	for	for	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
(	(	(	(	(	N	O
a	DT	a	a	a	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
three	CD	three	three	three	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
trial	NN	trial	trial	trial	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
sublingual	JJ	sublingual	sublingual	sublingu	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
was	VBD	was	wa	wa	N	O
administered	VBN	administered	administered	administ	N	O
in	IN	in	in	in	N	O
doses	NNS	doses	dos	dose	N	O
ranging	VBG	ranging	ranging	rang	N	O
from	IN	from	from	from	N	O
5	CD	5	5	5	N	O
to	TO	to	to	to	N	O
10	CD	10	10	10	N	O
mg	NNS	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Associated	NNP	associated	associated	associ	N	O
with	IN	with	with	with	N	O
Discontinuation	NNP	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
:	:	:	:	:	N	O
A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
9%	CD	9%	9%	9%	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
twice	RB	twice	twice	twice	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
rate	NN	rate	rate	rate	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Occurring	NNP	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
More	JJR	more	more	more	N	O
in	IN	in	in	in	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Schizophrenia	NNP	schizophrenia	schizophrenia	schizophrenia	Y	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
,	,	,	,	,	N	O
rounded	VBD	rounded	rounded	round	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
nearest	JJS	nearest	nearest	nearest	N	O
percent	NN	percent	percent	percent	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
incidence	NN	incidence	incidence	incid	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
during	IN	during	during	dure	N	O
acute	NN	acute	acute	acut	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
weeks	NNS	weeks	week	week	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
8	CD	8	8	8	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
8	CD	8	8	8	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
More	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
Adult	NNP	adult	adult	adult	N	O
Patients	NNPS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Any	NNP	any	any	ani	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
Dose	NNP	dose	dose	dose	N	O
Group	NNP	group	group	group	N	O
and	CC	and	and	and	N	O
Which	NNP	which	which	which	N	O
Occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
Greater	NNP	greater	greater	greater	N	O
Incidence	NNP	incidence	incidence	incid	N	O
Than	NNP	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Group	NNP	group	group	group	N	O
in	IN	in	in	in	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
Week	NN	week	week	week	N	O
Schizophrenia	NNP	schizophrenia	schizophrenia	schizophrenia	Y	O
Trials	NNS	trials	trial	trial	N	O

Akathisia	NNP	akathisia	akathisia	akathisia	Y	B-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
:	:	:	:	:	N	O
akathisia	NN	akathisia	akathisia	akathisia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hyperkinesia	NN	hyperkinesia	hyperkinesia	hyperkinesia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Extrapyramidal	NNP	extrapyramidal	extrapyramidal	extrapyramid	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
included	VBD	included	included	includ	N	O
dystonia	NN	dystonia	dystonia	dystonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
oculogyration	NN	oculogyration	oculogyration	oculogyr	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyskinesia	NN	dyskinesia	dyskinesia	dyskinesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
tardive	JJ	tardive	tardive	tardiv	N	B-AdverseReaction
dyskinesia	NN	dyskinesia	dyskinesia	dyskinesia	Y	I-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
rigidity	NN	rigidity	rigidity	rigid	Y	I-AdverseReaction
,	,	,	,	,	N	O
parkinsonism	NN	parkinsonism	parkinsonism	parkinson	Y	B-AdverseReaction
,	,	,	,	,	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
extrapyramidal	JJ	extrapyramidal	extrapyramidal	extrapyramid	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
excluding	VBG	excluding	excluding	exclud	N	B-Negation
akathisia	NN	akathisia	akathisia	akathisia	Y	B-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

?	.	?	?	?	N	O

Somnolence	NNP	somnolence	somnolence	somnol	Y	B-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
events	NNS	events	event	event	N	O
:	:	:	:	:	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypersomnia	NN	hypersomnia	hypersomnia	hypersomnia	Y	B-AdverseReaction
.	.	.	.	.	N	O

S	NNP	s	s	s	N	O
Also	RB	also	also	also	N	O
includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
Flexible	JJ	flexible	flexible	flexibl	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
90	CD	90	90	90	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

System	NN	system	system	system	N	O

Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
378	CD	378	378	378	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
N	NNP	n	n	n	N	O
274	CD	274	274	274	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
N	NNP	n	n	n	N	O
208	CD	208	208	208	N	O
All	NNP	all	all	all	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
S	NNP	s	s	s	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
N	NNP	n	n	n	N	O
572	CD	572	572	572	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
6	CD	6	6	6	N	O
7	CD	7	7	7	N	O
4	CD	4	4	4	N	O
5	CD	5	5	5	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
mouth	VBD	mouth	mouth	mouth	N	I-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O

Oral	JJ	oral	oral	oral	N	B-AdverseReaction
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	I-AdverseReaction
1	CD	1	1	1	N	O
6	CD	6	6	6	N	O
7	CD	7	7	7	N	O
5	CD	5	5	5	N	O

Salivary	JJ	salivary	salivary	salivari	N	B-AdverseReaction
hypersecretion	NN	hypersecretion	hypersecretion	hypersecret	N	I-AdverseReaction
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
4	CD	4	4	4	N	O
2	CD	2	2	2	N	O

Stomach	NNP	stomach	stomach	stomach	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
5	CD	5	5	5	N	O
4	CD	4	4	4	N	O
7	CD	7	7	7	N	O
5	CD	5	5	5	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
3	CD	3	3	3	N	O
3	CD	3	3	3	N	O

Irritability	NNP	irritability	irritability	irrit	Y	B-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
weight	VBD	weight	weight	weight	Y	I-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
disorders	NNS	disorders	disorder	disord	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Akathisia	$	akathisia	akathisia	akathisia	Y	B-AdverseReaction
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
11	CD	11	11	11	N	O
6	CD	6	6	6	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
4	CD	4	4	4	N	O
7	CD	7	7	7	N	O
3	CD	3	3	3	N	O
5	CD	5	5	5	N	O

Extrapyramidal	NNP	extrapyramidal	extrapyramidal	extrapyramid	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
(	(	(	(	(	N	O
excluding	VBG	excluding	excluding	exclud	N	B-Negation
akathisia	NN	akathisia	akathisia	akathisia	Y	B-AdverseReaction
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
9	CD	9	9	9	N	O
12	CD	12	12	12	N	O
10	CD	10	10	10	N	O

Somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
?	.	?	?	?	N	O

7	CD	7	7	7	N	O
15	CD	15	15	15	N	O
13	CD	13	13	13	N	O
13	CD	13	13	13	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
13	CD	13	13	13	N	O
16	CD	16	16	16	N	O
15	CD	15	15	15	N	O
15	CD	15	15	15	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Dose	NNP	dose	dose	dose	N	O
-	:	-	-	-	N	O
Related	JJ	related	related	relat	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
short	JJ	short	short	short	N	O
term	NN	term	term	term	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
trials	VBZ	trials	trial	trial	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
akathisia	NN	akathisia	akathisia	akathisia	Y	B-AdverseReaction
appeared	VBD	appeared	appeared	appear	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
(	(	(	(	(	N	O
seeTable	JJ	seetable	seetable	seetabl	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O

in	IN	in	in	in	N	O
Adult	NNP	adult	adult	adult	N	O
Patients	NNPS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Bipolar	NNP	bipolar	bipolar	bipolar	N	O
Mania	NNP	mania	mania	mania	Y	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
findings	NNS	findings	finding	find	N	O
are	VBP	are	are	are	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
for	IN	for	for	for	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
(	(	(	(	(	N	O
a	DT	a	a	a	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
two	CD	two	two	two	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
trials	NNS	trials	trial	trial	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
sublingual	JJ	sublingual	sublingual	sublingu	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
was	VBD	was	wa	wa	N	O
administered	VBN	administered	administered	administ	N	O
in	IN	in	in	in	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
5	CD	5	5	5	N	O
mg	NNS	mg	mg	mg	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Associated	NNP	associated	associated	associ	N	O
with	IN	with	with	with	N	O
Discontinuation	NNP	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
:	:	:	:	:	N	O
Approximately	RB	approximately	approximately	approxim	N	O
10%	CD	10%	10%	10%	N	O
(	(	(	(	(	N	O
38	CD	38	38	38	N	O
379	CD	379	379	379	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
about	RB	about	about	about	N	O
6%	CD	6%	6%	6%	N	O
(	(	(	(	(	N	O
12	CD	12	12	12	N	O
203	CD	203	203	203	N	O
)	)	)	)	)	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
(	(	(	(	(	N	O
rates	NNS	rates	rate	rate	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
twice	RB	twice	twice	twice	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
rate	NN	rate	rate	rate	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction
(	(	(	(	(	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	I-AdverseReaction
(	(	(	(	(	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O
)	)	)	)	)	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Occurring	NNP	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
More	JJR	more	more	more	N	O
Among	IN	among	among	among	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
Treated	VBN	treated	treated	treat	N	O
(	(	(	(	(	N	O
Monotherapy	NNP	monotherapy	monotherapy	monotherapi	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Bipolar	NNP	bipolar	bipolar	bipolar	N	O
I	PRP	i	i	i	N	O
Disorder	VBP	disorder	disorder	disord	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
,	,	,	,	,	N	O
rounded	VBD	rounded	rounded	round	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
nearest	JJS	nearest	nearest	nearest	N	O
percent	NN	percent	percent	percent	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
incidence	NN	incidence	incidence	incid	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
during	IN	during	during	dure	N	O
acute	NN	acute	acute	acut	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
(	(	(	(	(	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
weeks	NNS	weeks	week	week	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
9	CD	9	9	9	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
9	CD	9	9	9	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
More	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
Adult	NNP	adult	adult	adult	N	O
Patients	NNPS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Any	NNP	any	any	ani	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
Dose	NNP	dose	dose	dose	N	O
Group	NNP	group	group	group	N	O
and	CC	and	and	and	N	O
Which	NNP	which	which	which	N	O
Occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
Greater	NNP	greater	greater	greater	N	O
Incidence	NNP	incidence	incidence	incid	N	O
Than	NNP	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Group	NNP	group	group	group	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
Week	NN	week	week	week	N	O
Bipolar	NNP	bipolar	bipolar	bipolar	N	O
Mania	NNP	mania	mania	mania	Y	O
Trials	NNP	trials	trial	trial	N	O

SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
to	TO	to	to	to	N	O
10	CD	10	10	10	N	O
mg	NNS	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
with	IN	with	with	with	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
dosing	NN	dosing	dosing	dose	N	O
.	.	.	.	.	N	O

Extrapyramidal	NNP	extrapyramidal	extrapyramidal	extrapyramid	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
included	VBD	included	included	includ	N	O
:	:	:	:	:	N	O
dystonia	NN	dystonia	dystonia	dystonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
blepharospasm	NN	blepharospasm	blepharospasm	blepharospasm	Y	B-AdverseReaction
,	,	,	,	,	N	O
torticollis	NN	torticollis	torticollis	torticolli	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyskinesia	NN	dyskinesia	dyskinesia	dyskinesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
tardive	JJ	tardive	tardive	tardiv	N	B-AdverseReaction
dyskinesia	NN	dyskinesia	dyskinesia	dyskinesia	Y	I-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
rigidity	NN	rigidity	rigidity	rigid	Y	I-AdverseReaction
,	,	,	,	,	N	O
parkinsonism	NN	parkinsonism	parkinsonism	parkinson	Y	B-AdverseReaction
,	,	,	,	,	N	O
gait	NN	gait	gait	gait	N	B-AdverseReaction
disturbance	NN	disturbance	disturbance	disturb	N	I-AdverseReaction
,	,	,	,	,	N	O
masked	JJ	masked	masked	mask	N	B-AdverseReaction
facies	NNS	facies	facies	faci	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
(	(	(	(	(	N	O
excluding	VBG	excluding	excluding	exclud	N	B-Negation
akathisia	NN	akathisia	akathisia	akathisia	Y	B-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

?	.	?	?	?	N	O

Somnolence	NNP	somnolence	somnolence	somnol	Y	B-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
events	NNS	events	event	event	N	O
:	:	:	:	:	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypersomnia	NN	hypersomnia	hypersomnia	hypersomnia	Y	B-AdverseReaction
.	.	.	.	.	N	O

System	NN	system	system	system	N	O

Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
203	CD	203	203	203	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
N	NNP	n	n	n	N	O
379	CD	379	379	379	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
mouth	VBD	mouth	mouth	mouth	N	I-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
2	CD	2	2	2	N	O
4	CD	4	4	4	N	O

Oral	JJ	oral	oral	oral	N	B-AdverseReaction
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	I-AdverseReaction
1	CD	1	1	1	N	O
4	CD	4	4	4	N	O

Toothache	NNP	toothache	toothache	toothach	Y	B-AdverseReaction
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
2	CD	2	2	2	N	O
4	CD	4	4	4	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
weight	VBD	weight	weight	weight	Y	I-AdverseReaction
1	CD	1	1	1	N	O
5	CD	5	5	5	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
disorders	NNS	disorders	disorder	disord	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
1	CD	1	1	1	N	O
4	CD	4	4	4	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Akathisia	$	akathisia	akathisia	akathisia	Y	B-AdverseReaction
2	CD	2	2	2	N	O
4	CD	4	4	4	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
3	CD	3	3	3	N	O
11	CD	11	11	11	N	O

Dysgeusia	NNP	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
11	CD	11	11	11	N	O
12	CD	12	12	12	N	O

Other	JJ	other	other	other	N	O
extrapyramidal	NN	extrapyramidal	extrapyramidal	extrapyramid	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
(	(	(	(	(	N	O
excluding	VBG	excluding	excluding	exclud	N	B-Negation
akathisia	NN	akathisia	akathisia	akathisia	Y	B-AdverseReaction
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
7	CD	7	7	7	N	O

Somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
?	.	?	?	?	N	O

6	CD	6	6	6	N	O
24	CD	24	24	24	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O

Anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction
2	CD	2	2	2	N	O
4	CD	4	4	4	N	O

Depression	NNP	depression	depression	depress	Y	B-AdverseReaction
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
5	CD	5	5	5	N	O
6	CD	6	6	6	N	O

Monotherapy	NNP	monotherapy	monotherapy	monotherapi	N	O
in	IN	in	in	in	N	O
Pediatric	NNP	pediatric	pediatric	pediatr	N	O
Patients	NNPS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Bipolar	NNP	bipolar	bipolar	bipolar	N	O
Mania	NNP	mania	mania	mania	Y	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
findings	NNS	findings	finding	find	N	O
are	VBP	are	are	are	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
for	IN	for	for	for	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
was	VBD	was	wa	wa	N	O
administered	VBN	administered	administered	administ	N	O
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NNS	mg	mg	mg	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

Adverse	NN	adverse	adverse	advers	N	O

Reactions	NNS	reactions	reaction	reaction	N	O
Leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
Discontinuation	NNP	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
:	:	:	:	:	N	O
A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
6.7%	CD	6.7%	6.7%	6.7%	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
104	CD	104	104	104	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
5.1%	CD	5.1%	5.1%	5.1%	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
99	CD	99	99	99	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
5.1%	CD	5.1%	5.1%	5.1%	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
99	CD	99	99	99	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
4%	CD	4%	4%	4%	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
101	CD	101	101	101	N	O
)	)	)	)	)	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
(	(	(	(	(	N	O
rates	NNS	rates	rate	rate	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
arm	NN	arm	arm	arm	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
twice	RB	twice	twice	twice	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
rate	NN	rate	rate	rate	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
1%	CD	1%	1%	1%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
group	NN	group	group	group	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
group	NN	group	group	group	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
group	NN	group	group	group	N	O
)	)	)	)	)	N	O
No	DT	no	no	no	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
dropped	VBD	dropped	dropped	drop	N	O
out	RP	out	out	out	N	O
for	IN	for	for	for	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Occurring	VBG	occurring	occurring	occur	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
More	JJR	more	more	more	N	O
in	IN	in	in	in	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
Bipolar	JJ	bipolar	bipolar	bipolar	N	O
Patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
2%	CD	2%	2%	2%	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
dose	NN	dose	dose	dose	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
during	IN	during	during	dure	N	O
acute	NN	acute	acute	acut	N	O
therapy	NN	therapy	therapy	therapi	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
10	CD	10	10	10	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
10	CD	10	10	10	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
More	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
Pediatric	JJ	pediatric	pediatric	pediatr	N	O
Patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
Ages	$	ages	age	age	N	O
10	CD	10	10	10	N	O
to	TO	to	to	to	N	O
17	CD	17	17	17	N	O
Years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
Any	NNP	any	any	ani	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
Dose	NNP	dose	dose	dose	N	O
Group	NNP	group	group	group	N	O
and	CC	and	and	and	N	O
Which	NNP	which	which	which	N	O
Occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
Greater	NNP	greater	greater	greater	N	O
Incidence	NNP	incidence	incidence	incid	N	O
Than	NNP	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Group	NNP	group	group	group	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
Week	NN	week	week	week	N	O
Bipolar	NNP	bipolar	bipolar	bipolar	N	O
Mania	NNP	mania	mania	mania	Y	O
Trial	NNP	trial	trial	trial	N	O

1	CD	1	1	1	N	O
Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
heart	NN	heart	heart	heart	N	B-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
.	.	.	.	.	N	O

2	CD	2	2	2	N	O
Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	I-AdverseReaction
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
dysesthesia	NN	dysesthesia	dysesthesia	dysesthesia	Y	I-AdverseReaction
.	.	.	.	.	N	O

3	CD	3	3	3	N	O
Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
lower	JJR	lower	lower	lower	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
.	.	.	.	.	N	O

4	CD	4	4	4	N	O
Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
and	CC	and	and	and	N	O
lethargy	NN	lethargy	lethargy	lethargi	Y	B-AdverseReaction
.	.	.	.	.	N	O

5	CD	5	5	5	N	O
Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
hyperinsulinemia	NN	hyperinsulinemia	hyperinsulinemia	hyperinsulinemia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
blood	NN	blood	blood	blood	N	B-AdverseReaction
insulin	NN	insulin	insulin	insulin	Y	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
.	.	.	.	.	N	O

6	CD	6	6	6	N	O
Includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
preferred	JJ	preferred	preferred	prefer	N	O
terms	NNS	terms	term	term	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
,	,	,	,	,	N	O
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypersomnia	NN	hypersomnia	hypersomnia	hypersomnia	Y	B-AdverseReaction
.	.	.	.	.	N	O

System	NN	system	system	system	N	O

Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
AE	NNP	ae	ae	ae	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
101	CD	101	101	101	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
N	NNP	n	n	n	N	O
104	CD	104	104	104	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NNS	mg	mg	mg	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
N	NNP	n	n	n	N	O
99	CD	99	99	99	N	O
5	CD	5	5	5	N	O
mg	NNS	mg	mg	mg	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
N	NNP	n	n	n	N	O
99	CD	99	99	99	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
All	NNP	all	all	all	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
2.5	CD	2.5	2.5	2.5	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O

N	NNP	n	n	n	N	O
101	CD	101	101	101	N	O
N	NNP	n	n	n	N	O
104	CD	104	104	104	N	O
N	NNP	n	n	n	N	O
99	CD	99	99	99	N	O
N	NNP	n	n	n	N	O
99	CD	99	99	99	N	O
N	NNP	n	n	n	N	O
302	CD	302	302	302	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Tachycardia	NNP	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Oral	JJ	oral	oral	oral	N	B-AdverseReaction
paraesthesia	NN	paraesthesia	paraesthesia	paraesthesia	Y	I-AdverseReaction
2	CD	2	2	2	N	O
4	CD	4	4	4	N	O
25	CD	25	25	25	N	O
25	CD	25	25	25	N	O
30	CD	30	30	30	N	O
27	CD	27	27	27	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
3	CD	3	3	3	N	O
6	CD	6	6	6	N	O
6	CD	6	6	6	N	O
6	CD	6	6	6	N	O
6	CD	6	6	6	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
4	CD	4	4	4	N	O
4	CD	4	4	4	N	O
4	CD	4	4	4	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
3	CD	3	3	3	N	O
7	CD	7	7	7	N	O
9	CD	9	9	9	N	O
3	CD	3	3	3	N	O
5	CD	5	5	5	N	O
6	CD	6	6	6	N	O

Glossodynia	NNP	glossodynia	glossodynia	glossodynia	Y	B-AdverseReaction
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O

General	NNP	general	general	gener	N	O
Disorders	NNPS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Administrative	NNP	administrative	administrative	administr	N	O
Site	NNP	site	site	site	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
4	CD	4	4	4	N	O
5	CD	5	5	5	N	O
4	CD	4	4	4	N	O
8	CD	8	8	8	N	O
14	CD	14	14	14	N	O
9	CD	9	9	9	N	O

Irritability	NNP	irritability	irritability	irrit	Y	B-AdverseReaction
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Injury	NNP	injury	injury	injuri	Y	O
,	,	,	,	,	N	O
Poisoning	NNP	poisoning	poisoning	poison	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Procedural	NNP	procedural	procedural	procedur	N	O
Complications	NNP	complications	complication	complic	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
strain	VBD	strain	strain	strain	Y	I-AdverseReaction
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
weight	VBD	weight	weight	weight	Y	I-AdverseReaction
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O

Hyperinsulinemia	NNP	hyperinsulinemia	hyperinsulinemia	hyperinsulinemia	Y	B-AdverseReaction
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O

ALT	NNP	alt	alt	alt	N	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

AST	NNP	ast	ast	ast	N	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
Nutrition	NN	nutrition	nutrition	nutrit	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
2	CD	2	2	2	N	O
10	CD	10	10	10	N	O
9	CD	9	9	9	N	O
6	CD	6	6	6	N	O
8	CD	8	8	8	N	O

Dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Myalgia	NNP	myalgia	myalgia	myalgia	Y	B-AdverseReaction
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
6	CD	6	6	6	N	O
12	CD	12	12	12	N	O
46	CD	46	46	46	N	O
53	CD	53	53	53	N	O
49	CD	49	49	49	N	O
49	CD	49	49	49	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
6	CD	6	6	6	N	O
8	CD	8	8	8	N	O
11	CD	11	11	11	N	O
9	CD	9	9	9	N	O
9	CD	9	9	9	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
3	CD	3	3	3	N	O
6	CD	6	6	6	N	O
10	CD	10	10	10	N	O
5	CD	5	5	5	N	O
7	CD	7	7	7	N	O

Dysgeusia	NNP	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
2	CD	2	2	2	N	O
4	CD	4	4	4	N	O
5	CD	5	5	5	N	O
9	CD	9	9	9	N	O
6	CD	6	6	6	N	O

Akathisia	$	akathisia	akathisia	akathisia	Y	B-AdverseReaction
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O

Parkinsonism	NN	parkinsonism	parkinsonism	parkinson	Y	B-AdverseReaction
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
3	CD	3	3	3	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
3	CD	3	3	3	N	O
3	CD	3	3	3	N	O

Suicidal	NNP	suicidal	suicidal	suicid	N	B-AdverseReaction
ideation	NN	ideation	ideation	ideat	N	I-AdverseReaction
1	CD	1	1	1	N	O
4	CD	4	4	4	N	O
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O
3	CD	3	3	3	N	O

Anger	NNP	anger	anger	anger	Y	B-AdverseReaction
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Reproductive	JJ	reproductive	reproductive	reproduct	N	O
System	NNP	system	system	system	N	O
and	CC	and	and	and	N	O
Breast	NNP	breast	breast	breast	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Dysmenorrhea	NNP	dysmenorrhea	dysmenorrhea	dysmenorrhea	Y	B-AdverseReaction
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
Thoracic	NNP	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Mediastinal	NNP	mediastinal	mediastinal	mediastin	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Oropharyngeal	NNP	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
1	CD	1	1	1	N	O
1	CD	1	1	1	N	O

Nasal	NNP	nasal	nasal	nasal	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Dose	NNP	dose	dose	dose	N	O
-	:	-	-	-	N	O
Related	JJ	related	related	relat	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
short	JJ	short	short	short	N	O
term	NN	term	term	term	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
trials	NNS	trials	trial	trial	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
appeared	VBD	appeared	appeared	appear	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O

Adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O

Therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
Adult	NNP	adult	adult	adult	N	O
Patients	NNPS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Bipolar	NNP	bipolar	bipolar	bipolar	N	O
Mania	NNP	mania	mania	mania	Y	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
findings	NNS	findings	finding	find	N	O
are	VBP	are	are	are	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
12	CD	12	12	12	N	O
week	NN	week	week	week	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
week	NN	week	week	week	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
endpoint	NN	endpoint	endpoint	endpoint	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
adult	NN	adult	adult	adult	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
sublingual	JJ	sublingual	sublingual	sublingu	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
was	VBD	was	wa	wa	N	O
administered	VBN	administered	administered	administ	N	O
in	IN	in	in	in	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
5	CD	5	5	5	N	O
mg	NNS	mg	mg	mg	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
as	IN	as	a	as	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
lithium	NN	lithium	lithium	lithium	N	O
or	CC	or	or	or	N	O
valproate	NN	valproate	valproate	valproat	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Associated	NNP	associated	associated	associ	N	O
with	IN	with	with	with	N	O
Discontinuation	NNP	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
:	:	:	:	:	N	O
Approximately	RB	approximately	approximately	approxim	N	O
16%	CD	16%	16%	16%	N	O
(	(	(	(	(	N	O
25	CD	25	25	25	N	O
158	CD	158	158	158	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
about	RB	about	about	about	N	O
11%	CD	11%	11%	11%	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
166	CD	166	166	166	N	O
)	)	)	)	)	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
(	(	(	(	(	N	O
rates	NNS	rates	rate	rate	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
twice	RB	twice	twice	twice	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
rate	NN	rate	rate	rate	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
(	(	(	(	(	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
suicidal	JJ	suicidal	suicidal	suicid	N	B-AdverseReaction
ideation	NN	ideation	ideation	ideat	N	I-AdverseReaction
(	(	(	(	(	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	B-AdverseReaction
I	PRP	i	i	i	N	I-AdverseReaction
disorder	VBP	disorder	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
1.9%	CD	1.9%	1.9%	1.9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
insomnia	NN	insomnia	insomnia	insomnia	Y	B-AdverseReaction
(	(	(	(	(	N	O
1.9%	CD	1.9%	1.9%	1.9%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
depressive	JJ	depressive	depressive	depress	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
(	(	(	(	(	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Occurring	NNP	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
More	JJR	more	more	more	N	O
Among	IN	among	among	among	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
Treated	VBN	treated	treated	treat	N	O
(	(	(	(	(	N	O
Adjunctive	NNP	adjunctive	adjunctive	adjunct	N	O
)	)	)	)	)	N	O
Bipolar	JJ	bipolar	bipolar	bipolar	N	O
Patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
(	(	(	(	(	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
,	,	,	,	,	N	O
rounded	VBD	rounded	rounded	round	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
nearest	JJS	nearest	nearest	nearest	N	O
percent	NN	percent	percent	percent	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
incidence	NN	incidence	incidence	incid	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
during	IN	during	during	dure	N	O
acute	JJ	acute	acute	acut	N	O
adjunctive	JJ	adjunctive	adjunctive	adjunct	N	O
therapy	NN	therapy	therapy	therapi	N	O
at	IN	at	at	at	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
time	NN	time	time	time	N	O
when	WRB	when	when	when	N	O
most	JJS	most	most	most	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
still	RB	still	still	still	N	O
participating	VBG	participating	participating	particip	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
11	CD	11	11	11	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
11	CD	11	11	11	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
or	CC	or	or	or	N	O
More	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
Adult	NNP	adult	adult	adult	N	O
Patients	NNPS	patients	patient	patient	N	O
In	IN	in	in	in	N	O
Any	NNP	any	any	ani	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
Dose	NNP	dose	dose	dose	N	O
Group	NNP	group	group	group	N	O
and	CC	and	and	and	N	O
Which	NNP	which	which	which	N	O
Occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
Greater	NNP	greater	greater	greater	N	O
Incidence	NNP	incidence	incidence	incid	N	O
Than	NNP	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Group	NNP	group	group	group	N	O
at	IN	at	at	at	N	O
3	CD	3	3	3	N	O
Weeks	NNP	weeks	week	week	N	O
in	IN	in	in	in	N	O
Adjunctive	NNP	adjunctive	adjunctive	adjunct	N	O
Bipolar	NNP	bipolar	bipolar	bipolar	N	O
Mania	NNP	mania	mania	mania	Y	O
Trials	NNP	trials	trial	trial	N	O

SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
to	TO	to	to	to	N	O
10	CD	10	10	10	N	O
mg	NNS	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
with	IN	with	with	with	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
dosing	NN	dosing	dosing	dose	N	O
.	.	.	.	.	N	O

Extrapyramidal	NNP	extrapyramidal	extrapyramidal	extrapyramid	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
included	VBD	included	included	includ	N	O
:	:	:	:	:	N	O
dystonia	NN	dystonia	dystonia	dystonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
parkinsonism	NN	parkinsonism	parkinsonism	parkinson	Y	B-AdverseReaction
,	,	,	,	,	N	O
oculogyration	NN	oculogyration	oculogyration	oculogyr	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
(	(	(	(	(	N	O
excluding	VBG	excluding	excluding	exclud	N	B-Negation
akathisia	NN	akathisia	akathisia	akathisia	Y	B-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

?	.	?	?	?	N	O

Somnolence	NNP	somnolence	somnolence	somnol	Y	B-AdverseReaction
includes	VBZ	includes	includes	includ	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
events	NNS	events	event	event	N	O
:	:	:	:	:	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
and	CC	and	and	and	N	O
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
.	.	.	.	.	N	O

System	NN	system	system	system	N	O

Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
166	CD	166	166	166	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
N	NNP	n	n	n	N	O
158	CD	158	158	158	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
2	CD	2	2	2	N	O
3	CD	3	3	3	N	O

Oral	JJ	oral	oral	oral	N	B-AdverseReaction
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	I-AdverseReaction
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
2	CD	2	2	2	N	O
4	CD	4	4	4	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
peripheral	JJ	peripheral	peripheral	peripher	N	I-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
weight	VBD	weight	weight	weight	Y	I-AdverseReaction
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
2	CD	2	2	2	N	O
4	CD	4	4	4	N	O

Other	JJ	other	other	other	N	O
extrapyramidal	NN	extrapyramidal	extrapyramidal	extrapyramid	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
(	(	(	(	(	N	O
excluding	VBG	excluding	excluding	exclud	N	B-Negation
akathisia	NN	akathisia	akathisia	akathisia	Y	B-AdverseReaction
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
6	CD	6	6	6	N	O

Somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
?	.	?	?	?	N	O

10	CD	10	10	10	N	O
22	CD	22	22	22	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
8	CD	8	8	8	N	O
10	CD	10	10	10	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
1	CD	1	1	1	N	O
3	CD	3	3	3	N	O

Dystonia	NN	dystonia	dystonia	dystonia	Y	O
:	:	:	:	:	N	O
Symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
dystonia	NN	dystonia	dystonia	dystonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
prolonged	VBD	prolonged	prolonged	prolong	N	B-AdverseReaction
abnormal	JJ	abnormal	abnormal	abnorm	N	I-AdverseReaction
contractions	NNS	contractions	contraction	contract	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
muscle	NN	muscle	muscle	muscl	N	I-AdverseReaction
groups	NNS	groups	group	group	N	I-AdverseReaction
,	,	,	,	,	N	O
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
susceptible	JJ	susceptible	susceptible	suscept	N	O
individuals	NNS	individuals	individual	individu	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
few	JJ	few	few	few	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Dystonic	NNP	dystonic	dystonic	dyston	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
include	VBP	include	include	includ	N	O
:	:	:	:	:	N	O
spasm	NN	spasm	spasm	spasm	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
neck	NN	neck	neck	neck	N	I-AdverseReaction
muscles	NNS	muscles	muscle	muscl	N	I-AdverseReaction
,	,	,	,	,	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
progressing	VBG	progressing	progressing	progress	N	O
to	TO	to	to	to	N	O
tightness	NN	tightness	tightness	tight	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
throat	NN	throat	throat	throat	N	I-AdverseReaction
,	,	,	,	,	N	O
swallowing	VBG	swallowing	swallowing	swallow	N	B-AdverseReaction
difficulty	NN	difficulty	difficulty	difficulti	N	I-AdverseReaction
,	,	,	,	,	N	O
difficulty	NN	difficulty	difficulty	difficulti	N	B-AdverseReaction
breathing	NN	breathing	breathing	breath	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
protrusion	NN	protrusion	protrusion	protrus	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
tongue	NN	tongue	tongue	tongu	N	I-AdverseReaction
.	.	.	.	.	N	O

While	IN	while	while	while	N	O
these	DT	these	these	these	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
at	IN	at	at	at	N	O
low	JJ	low	low	low	N	O
doses	NNS	doses	dos	dose	N	O
,	,	,	,	,	N	O
they	PRP	they	they	they	N	O
occur	VBP	occur	occur	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
greater	JJR	greater	greater	greater	N	O
severity	NN	severity	severity	sever	N	O
with	IN	with	with	with	N	O
high	JJ	high	high	high	N	O
potency	NN	potency	potency	potenc	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
higher	JJR	higher	higher	higher	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
first	JJ	first	first	first	N	O
generation	NN	generation	generation	gener	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drugs	NNS	drugs	drug	drug	N	O
.	.	.	.	.	N	O

An	DT	an	an	an	N	O
elevated	JJ	elevated	elevated	elev	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
dystonia	NN	dystonia	dystonia	dystonia	Y	I-AdverseReaction
is	VBZ	is	is	is	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
males	NNS	males	male	male	N	O
and	CC	and	and	and	N	O
younger	JJR	younger	younger	younger	N	O
age	NN	age	age	age	N	O
groups	NNS	groups	group	group	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.4	CD	8.4	8.4	8.4	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Extrapyramidal	NN	extrapyramidal	extrapyramidal	extrapyramid	N	O

Symptoms	NNS	symptoms	symptom	symptom	N	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
and	CC	and	and	and	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
adult	NN	adult	adult	adult	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
data	NNS	data	data	data	N	O
was	VBD	was	wa	wa	N	O
objectively	RB	objectively	objectively	object	N	O
collected	VBN	collected	collected	collect	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
Simpson	NNP	simpson	simpson	simpson	N	O
Angus	NNP	angus	angus	angu	N	O
Rating	NNP	rating	rating	rate	N	O
Scale	NNP	scale	scale	scale	N	O
for	IN	for	for	for	N	O
extrapyramidal	NN	extrapyramidal	extrapyramidal	extrapyramid	N	B-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
(	(	(	(	(	N	O
EPS	NNP	eps	eps	ep	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
Barnes	NNP	barnes	barnes	barn	N	O
Akathisia	NNP	akathisia	akathisia	akathisia	Y	O
Scale	NNP	scale	scale	scale	N	O
(	(	(	(	(	N	O
for	IN	for	for	for	N	O
akathisia	NN	akathisia	akathisia	akathisia	Y	B-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
Assessments	NNS	assessments	assessment	assess	N	O
of	IN	of	of	of	N	O
Involuntary	NNP	involuntary	involuntary	involuntari	N	O
Movement	NNP	movement	movement	movement	N	O
Scales	NNP	scales	scale	scale	Y	O
(	(	(	(	(	N	O
for	IN	for	for	for	N	O
dyskinesias	NN	dyskinesias	dyskinesia	dyskinesia	N	B-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
all	DT	all	all	all	N	O
-	:	-	-	-	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
treated	VBN	treated	treated	treat	N	O
group	NN	group	group	group	N	O
was	VBD	was	wa	wa	N	O
comparable	JJ	comparable	comparable	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
each	DT	each	each	each	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
rating	NN	rating	rating	rate	N	O
scale	NN	scale	scale	scale	N	O
scores	NNS	scores	score	score	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
adult	NN	adult	adult	adult	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
reported	VBN	reported	reported	report	N	O
EPS	NNP	eps	eps	ep	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	O
excluding	VBG	excluding	excluding	exclud	N	B-Negation
events	NNS	events	event	event	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
akathisia	VB	akathisia	akathisia	akathisia	Y	B-AdverseReaction
,	,	,	,	,	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
10%	CD	10%	10%	10%	N	O
versus	NN	versus	versus	versu	N	O
7%	CD	7%	7%	7%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
akathisia	JJ	akathisia	akathisia	akathisia	Y	B-AdverseReaction
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
events	NNS	events	event	event	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
6%	CD	6%	6%	6%	N	O
versus	NN	versus	versus	versu	N	O
3%	CD	3%	3%	3%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
adult	NN	adult	adult	adult	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
EPS	NNP	eps	eps	ep	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	O
excluding	VBG	excluding	excluding	exclud	N	B-Negation
events	NNS	events	event	event	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
akathisia	VB	akathisia	akathisia	akathisia	Y	B-AdverseReaction
,	,	,	,	,	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
7%	CD	7%	7%	7%	N	O
versus	NN	versus	versus	versu	N	O
2%	CD	2%	2%	2%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
akathisia	JJ	akathisia	akathisia	akathisia	Y	B-AdverseReaction
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
events	NNS	events	event	event	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
4%	CD	4%	4%	4%	N	O
versus	NN	versus	versus	versu	N	O
2%	CD	2%	2%	2%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
trial	NN	trial	trial	trial	N	O
with	IN	with	with	with	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
I	PRP	i	i	i	N	O
disorder	VBP	disorder	disorder	disord	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidences	NNS	incidences	incidence	incid	N	O
of	IN	of	of	of	N	O
EPS	NNP	eps	eps	ep	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	O
excluding	VBG	excluding	excluding	exclud	N	B-Negation
events	NNS	events	event	event	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
akathisia	NNS	akathisia	akathisia	akathisia	Y	B-AdverseReaction
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
4%	CD	4%	4%	4%	N	O
,	,	,	,	,	N	O
3%	CD	3%	3%	3%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
5%	CD	5%	5%	5%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
3%	CD	3%	3%	3%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

EPS	NNP	eps	eps	ep	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
include	VBP	include	include	includ	N	O
:	:	:	:	:	N	O
bradykinesia	NN	bradykinesia	bradykinesia	bradykinesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyskinesia	NN	dyskinesia	dyskinesia	dyskinesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dystonia	NN	dystonia	dystonia	dystonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
oromandibular	JJ	oromandibular	oromandibular	oromandibular	N	B-AdverseReaction
dystonia	NN	dystonia	dystonia	dystonia	Y	I-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
contractions	NNS	contractions	contraction	contract	N	I-AdverseReaction
involuntary	JJ	involuntary	involuntary	involuntari	N	I-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
twitching	NN	twitching	twitching	twitch	Y	I-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
stiffness	NN	stiffness	stiffness	stiff	Y	I-AdverseReaction
,	,	,	,	,	N	O
parkinsonism	NN	parkinsonism	parkinsonism	parkinson	Y	B-AdverseReaction
,	,	,	,	,	N	O
protrusion	NN	protrusion	protrusion	protrus	N	B-AdverseReaction
tongue	NN	tongue	tongue	tongu	N	I-AdverseReaction
,	,	,	,	,	N	O
resting	VBG	resting	resting	rest	N	B-AdverseReaction
tremor	NN	tremor	tremor	tremor	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
events	NNS	events	event	event	N	O
of	IN	of	of	of	N	O
akathisia	NN	akathisia	akathisia	akathisia	Y	B-AdverseReaction
,	,	,	,	,	N	O
incidences	NNS	incidences	incidence	incid	N	O
were	VBD	were	were	were	N	O
2%	CD	2%	2%	2%	N	O
,	,	,	,	,	N	O
2%	CD	2%	2%	2%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0%	CD	0%	0%	0%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
Findings	NNS	findings	finding	find	N	O
:	:	:	:	:	N	O
Oral	NNP	oral	oral	oral	N	B-AdverseReaction
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	I-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	I-AdverseReaction
may	MD	may	may	may	N	O
occur	VB	occur	occur	occur	N	O
directly	RB	directly	directly	directli	N	O
after	IN	after	after	after	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
and	CC	and	and	and	N	O
usually	RB	usually	usually	usual	N	O
resolves	NNS	resolves	resolve	resolv	N	O
within	IN	within	within	within	N	O
1	CD	1	1	1	N	O
hour	NN	hour	hour	hour	N	O
.	.	.	.	.	N	O

Laboratory	JJ	laboratory	laboratory	laboratori	N	O
Test	NNP	test	test	test	N	O
Abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
:	:	:	:	:	N	O

Transaminases	NNS	transaminases	transaminase	transaminas	Y	O
:	:	:	:	:	N	O
Transient	NN	transient	transient	transient	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	NN	serum	serum	serum	N	I-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
(	(	(	(	(	N	O
primarily	RB	primarily	primarily	primarili	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
and	CC	and	and	and	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
adult	NN	adult	adult	adult	N	O
trials	NNS	trials	trial	trial	N	O
were	VBD	were	were	were	N	O
more	JJR	more	more	more	N	O
common	JJ	common	common	common	N	O
in	IN	in	in	in	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
adult	NN	adult	adult	adult	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
1.6	CD	1.6	1.6	1.6	N	O
units	NNS	units	unit	unit	N	O
L	NNP	l	l	l	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
decrease	NN	decrease	decrease	decreas	N	O
of	IN	of	of	of	N	O
0.4	CD	0.4	0.4	0.4	N	O
units	NNS	units	unit	unit	N	O
L	NNP	l	l	l	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
transaminase	JJ	transaminase	transaminase	transaminas	N	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
3	CD	3	3	3	N	B-Severity
times	NNS	times	time	time	N	I-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
(	(	(	(	(	N	O
at	IN	at	at	at	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
versus	VBP	versus	versus	versu	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
adult	NN	adult	adult	adult	N	O
mania	NN	mania	mania	mania	Y	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
transaminase	NN	transaminase	transaminase	transaminas	N	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
8.9	CD	8.9	8.9	8.9	N	O
units	NNS	units	unit	unit	N	O
L	NNP	l	l	l	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
decrease	NN	decrease	decrease	decreas	N	O
of	IN	of	of	of	N	O
4.9	CD	4.9	4.9	4.9	N	O
units	NNS	units	unit	unit	N	O
L	NNP	l	l	l	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
transaminase	JJ	transaminase	transaminase	transaminas	N	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
3	CD	3	3	3	N	B-Severity
times	NNS	times	time	time	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
(	(	(	(	(	N	I-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
)	)	)	)	)	N	I-Severity
(	(	(	(	(	N	O
at	IN	at	at	at	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
versus	VBP	versus	versus	versu	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
52	CD	52	52	52	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
comparator	NN	comparator	comparator	compar	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
that	WDT	that	that	that	N	O
included	VBD	included	included	includ	N	O
primarily	RB	primarily	primarily	primarili	N	O
adult	VBN	adult	adult	adult	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
of	IN	of	of	of	N	I-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
1.7	CD	1.7	1.7	1.7	N	B-Severity
units	NNS	units	unit	unit	N	I-Severity
L.	NNP	l.	l.	l.	N	I-Severity

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
trial	NN	trial	trial	trial	N	O
with	IN	with	with	with	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
I	PRP	i	i	i	N	O
disorder	VBP	disorder	disorder	disord	N	O
,	,	,	,	,	N	O
transient	JJ	transient	transient	transient	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	NN	serum	serum	serum	N	I-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
(	(	(	(	(	N	O
primarily	RB	primarily	primarily	primarili	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
more	JJR	more	more	more	N	O
common	JJ	common	common	common	N	O
in	IN	in	in	in	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
3	CD	3	3	3	N	B-Severity
times	NNS	times	time	time	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
(	(	(	(	(	N	I-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
)	)	)	)	)	N	I-Severity
was	VBD	was	wa	wa	N	O
2.4%	CD	2.4%	2.4%	2.4%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	JJ	daily	daily	daili	N	O
versus	NN	versus	versus	versu	N	O
none	NN	none	none	none	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
other	JJ	other	other	other	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
dose	NN	dose	dose	dose	N	O
groups	NNS	groups	group	group	N	O
and	CC	and	and	and	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Prolactin	NN	prolactin	prolactin	prolactin	Y	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
adult	NN	adult	adult	adult	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	NN	mean	mean	mean	N	O
decreases	VBZ	decreases	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
prolactin	NN	prolactin	prolactin	prolactin	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
were	VBD	were	were	were	N	O
6.5	CD	6.5	6.5	6.5	N	O
ng	JJ	ng	ng	ng	N	O
mL	NN	ml	ml	ml	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
10.7	CD	10.7	10.7	10.7	N	O
ng	NNS	ng	ng	ng	N	O
mL	NN	ml	ml	ml	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
prolactin	JJ	prolactin	prolactin	prolactin	Y	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
4	CD	4	4	4	N	B-Severity
times	NNS	times	time	time	N	I-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
(	(	(	(	(	N	O
at	IN	at	at	at	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
2.6%	CD	2.6%	2.6%	2.6%	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
versus	VBP	versus	versus	versu	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
adult	NN	adult	adult	adult	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
prolactin	NN	prolactin	prolactin	prolactin	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
4.9	CD	4.9	4.9	4.9	N	O
ng	JJ	ng	ng	ng	N	O
mL	NN	ml	ml	ml	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
decrease	NN	decrease	decrease	decreas	N	O
of	IN	of	of	of	N	O
0.2	CD	0.2	0.2	0.2	N	O
ng	NNS	ng	ng	ng	N	O
mL	NN	ml	ml	ml	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
prolactin	JJ	prolactin	prolactin	prolactin	Y	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
4	CD	4	4	4	N	B-Severity
times	NNS	times	time	time	N	I-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
(	(	(	(	(	N	O
at	IN	at	at	at	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
versus	VBP	versus	versus	versu	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
(	(	(	(	(	N	O
52	CD	52	52	52	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
comparator	NN	comparator	comparator	compar	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
adult	NN	adult	adult	adult	N	O
trial	NN	trial	trial	trial	N	O
that	WDT	that	that	that	N	O
included	VBD	included	included	includ	N	O
primarily	RB	primarily	primarily	primarili	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
decrease	NN	decrease	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
prolactin	NN	prolactin	prolactin	prolactin	Y	I-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
26.9	CD	26.9	26.9	26.9	N	O
ng	JJ	ng	ng	ng	N	O
mL	NN	ml	ml	ml	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
trial	NN	trial	trial	trial	N	O
with	IN	with	with	with	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
I	PRP	i	i	i	N	O
disorder	VBP	disorder	disorder	disord	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	NN	mean	mean	mean	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
(	(	(	(	(	N	O
at	IN	at	at	at	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	I-AdverseReaction
prolactin	NN	prolactin	prolactin	prolactin	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
were	VBD	were	were	were	N	O
3.2	CD	3.2	3.2	3.2	N	O
ng	JJ	ng	ng	ng	N	O
mL	NN	ml	ml	ml	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
2.1	CD	2.1	2.1	2.1	N	O
ng	NN	ng	ng	ng	N	O
mL	NN	ml	ml	ml	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
6.4	CD	6.4	6.4	6.4	N	O
ng	NNS	ng	ng	ng	N	O
mL	NN	ml	ml	ml	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
of	IN	of	of	of	N	O
2.5	CD	2.5	2.5	2.5	N	O
ng	NNS	ng	ng	ng	N	O
mL	NN	ml	ml	ml	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	B-Negation
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
prolactin	JJ	prolactin	prolactin	prolactin	Y	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
4	CD	4	4	4	N	B-Severity
times	NNS	times	time	time	N	I-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
(	(	(	(	(	N	O
at	IN	at	at	at	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Galactorrhea	NNP	galactorrhea	galactorrhea	galactorrhea	Y	B-AdverseReaction
or	CC	or	or	or	N	O
dysmenorrhea	NN	dysmenorrhea	dysmenorrhea	dysmenorrhea	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0%	CD	0%	0%	0%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	B-Negation
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
gynecomastia	NN	gynecomastia	gynecomastia	gynecomastia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

Creatine	NNP	creatine	creatine	creatin	Y	O
Kinase	NNP	kinase	kinase	kinas	N	O
(	(	(	(	(	N	O
CK	NNP	ck	ck	ck	Y	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
adult	NN	adult	adult	adult	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CK	NNP	ck	ck	ck	Y	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
3	CD	3	3	3	N	B-Severity
times	NNS	times	time	time	N	I-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
at	IN	at	at	at	N	O
any	DT	any	any	ani	N	O
time	NN	time	time	time	N	O
were	VBD	were	were	were	N	O
6.4%	CD	6.4%	6.4%	6.4%	N	O
and	CC	and	and	and	N	O
11.1%	CD	11.1%	11.1%	11.1%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
and	CC	and	and	and	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
6.7%	CD	6.7%	6.7%	6.7%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
and	CC	and	and	and	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
relevance	NN	relevance	relevance	relev	N	O
of	IN	of	of	of	N	O
this	DT	this	this	thi	N	O
finding	NN	finding	finding	find	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CK	NNP	ck	ck	ck	Y	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
3	CD	3	3	3	N	B-Severity
times	NNS	times	time	time	N	I-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
during	IN	during	during	dure	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
bipolar	NN	bipolar	bipolar	bipolar	N	O
I	PRP	i	i	i	N	O
disorder	VBP	disorder	disorder	disord	N	O
at	IN	at	at	at	N	O
any	DT	any	any	ani	N	O
time	NN	time	time	time	N	O
were	VBD	were	were	were	N	O
1%	CD	1%	1%	1%	N	O
,	,	,	,	,	N	O
0%	CD	0%	0%	0%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
versus	VBZ	versus	versus	versu	N	O
3%	CD	3%	3%	3%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Observed	NNP	observed	observed	observ	N	O
During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
Premarketing	NNP	premarketing	premarketing	premarket	N	O
Evaluation	NNP	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
:	:	:	:	:	N	O
Following	NNP	following	following	follow	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
list	NN	list	list	list	N	O
of	IN	of	of	of	N	O
MedDRA	NNP	meddra	meddra	meddra	N	O
terms	NNS	terms	term	term	N	O
that	WDT	that	that	that	N	O
reflect	VBP	reflect	reflect	reflect	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
sublingual	JJ	sublingual	sublingual	sublingu	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
at	IN	at	at	at	N	O
multiple	JJ	multiple	multiple	multipl	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
5	CD	5	5	5	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
during	IN	during	during	dure	N	O
any	DT	any	any	ani	N	O
phase	NN	phase	phase	phase	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
trial	NN	trial	trial	trial	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
database	NN	database	database	databas	N	O
of	IN	of	of	of	N	O
adult	NN	adult	adult	adult	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
reactions	NNS	reactions	reaction	reaction	N	O
listed	VBN	listed	listed	list	N	O
are	VBP	are	are	are	N	O
those	DT	those	those	those	N	O
that	WDT	that	that	that	N	O
could	MD	could	could	could	N	O
be	VB	be	be	be	N	O
of	IN	of	of	of	N	O
clinical	JJ	clinical	clinical	clinic	N	O
importance	NN	importance	importance	import	N	O
,	,	,	,	,	N	O
as	RB	as	a	as	N	O
well	RB	well	well	well	N	O
as	IN	as	a	as	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
plausibly	RB	plausibly	plausibly	plausibl	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
on	IN	on	on	on	N	O
pharmacologic	NN	pharmacologic	pharmacologic	pharmacolog	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
grounds	NNS	grounds	ground	ground	N	O
.	.	.	.	.	N	O

Reactions	NNS	reactions	reaction	reaction	N	O
already	RB	already	already	alreadi	N	O
listed	VBN	listed	listed	list	N	O
for	IN	for	for	for	N	O
either	DT	either	either	either	N	O
adults	NNS	adults	adult	adult	N	O
or	CC	or	or	or	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
parts	NNS	parts	part	part	N	O
of	IN	of	of	of	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
those	DT	those	those	those	N	O
considered	VBN	considered	considered	consid	N	O
in	IN	in	in	in	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
Overdosage	NNP	overdosage	overdosage	overdosag	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
included	VBN	included	included	includ	N	O
.	.	.	.	.	N	O

Reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
further	JJ	further	further	further	N	O
categorized	VBN	categorized	categorized	categor	N	O
by	IN	by	by	by	N	O
MedDRA	NNP	meddra	meddra	meddra	N	O
system	NN	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O
and	CC	and	and	and	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
order	NN	order	order	order	N	O
of	IN	of	of	of	N	O
decreasing	VBG	decreasing	decreasing	decreas	N	O
frequency	NN	frequency	frequency	frequenc	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
definitions	NNS	definitions	definition	definit	N	O
:	:	:	:	:	N	O
those	DT	those	those	those	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
100	CD	100	100	100	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
frequent	JJ	frequent	frequent	frequent	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
only	RB	only	only	onli	N	O
those	DT	those	those	those	N	O
not	RB	not	not	not	N	O
already	RB	already	already	alreadi	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
tabulated	JJ	tabulated	tabulated	tabul	N	O
results	NNS	results	result	result	N	O
from	IN	from	from	from	N	O
placebo	JJ	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
appear	VBP	appear	appear	appear	N	O
in	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
listing	NN	listing	listing	list	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
those	DT	those	those	those	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
100	CD	100	100	100	N	O
to	TO	to	to	to	N	O
1	CD	1	1	1	N	O
1000	CD	1000	1000	1000	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
infrequent	NN	infrequent	infrequent	infrequ	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
those	DT	those	those	those	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
fewer	JJR	fewer	fewer	fewer	N	O
than	IN	than	than	than	N	O
1	CD	1	1	1	N	O
1000	CD	1000	1000	1000	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
rare	JJ	rare	rare	rare	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
infrequent	NN	infrequent	infrequent	infrequ	N	O
:	:	:	:	:	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
;	:	;	;	;	N	O
rare	JJ	rare	rare	rare	N	O
:	:	:	:	:	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
infrequent	NN	infrequent	infrequent	infrequ	N	O
:	:	:	:	:	N	O
temporary	JJ	temporary	temporary	temporari	N	B-AdverseReaction
bundle	NN	bundle	bundle	bundl	N	I-AdverseReaction
branch	NN	branch	branch	branch	N	I-AdverseReaction
block	NN	block	block	block	N	I-AdverseReaction

Eye	JJ	eye	eye	eye	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
infrequent	NN	infrequent	infrequent	infrequ	N	O
:	:	:	:	:	N	O
accommodation	NN	accommodation	accommodation	accommod	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
infrequent	NN	infrequent	infrequent	infrequ	N	O
:	:	:	:	:	N	O
swollen	JJ	swollen	swollen	swollen	N	B-AdverseReaction
tongue	NN	tongue	tongue	tongu	N	I-AdverseReaction

General	JJ	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
rare	NN	rare	rare	rare	N	O
:	:	:	:	:	N	O
idiosyncratic	JJ	idiosyncratic	idiosyncratic	idiosyncrat	N	B-AdverseReaction
drug	NN	drug	drug	drug	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction

Investigations	NNS	investigations	investigation	investig	N	O
:	:	:	:	:	N	O
infrequent	NN	infrequent	infrequent	infrequ	N	O
:	:	:	:	:	N	O
hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
infrequent	NN	infrequent	infrequent	infrequ	N	O
:	:	:	:	:	N	O
dysarthria	NN	dysarthria	dysarthria	dysarthria	Y	B-AdverseReaction

Following	VBG	following	following	follow	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
list	NN	list	list	list	N	O
of	IN	of	of	of	N	O
MedDRA	NNP	meddra	meddra	meddra	N	O
terms	NNS	terms	term	term	N	O
not	RB	not	not	not	N	O
already	RB	already	already	alreadi	N	O
listed	VBN	listed	listed	list	N	O
either	RB	either	either	either	N	O
for	IN	for	for	for	N	O
adults	NNS	adults	adult	adult	N	O
or	CC	or	or	or	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
parts	NNS	parts	part	part	N	O
of	IN	of	of	of	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
those	DT	those	those	those	N	O
considered	VBN	considered	considered	consid	N	O
in	IN	in	in	in	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
Overdosage	NNP	overdosage	overdosage	overdosag	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O
that	WDT	that	that	that	N	O
reflect	VBP	reflect	reflect	reflect	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
Ages	$	ages	age	age	N	O
10	CD	10	10	10	N	O
to	TO	to	to	to	N	O
17	CD	17	17	17	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
sublingual	JJ	sublingual	sublingual	sublingu	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NNS	mg	mg	mg	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
during	IN	during	during	dure	N	O
any	DT	any	any	ani	N	O
phase	NN	phase	phase	phase	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
trial	NN	trial	trial	trial	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
database	NN	database	database	databas	N	O
of	IN	of	of	of	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Eye	NN	eye	eye	eye	N	O

disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
infrequent	NN	infrequent	infrequent	infrequ	N	O
:	:	:	:	:	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	B-AdverseReaction
,	,	,	,	,	N	O
vision	NN	vision	vision	vision	N	B-AdverseReaction
blurred	VBD	blurred	blurred	blur	N	I-AdverseReaction

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
infrequent	NN	infrequent	infrequent	infrequ	N	O
:	:	:	:	:	N	O
gastroesophageal	NN	gastroesophageal	gastroesophageal	gastroesophag	N	B-AdverseReaction
reflux	NN	reflux	reflux	reflux	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction

Injury	NNP	injury	injury	injuri	Y	O
,	,	,	,	,	N	O
Poisoning	NNP	poisoning	poisoning	poison	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Procedural	JJ	procedural	procedural	procedur	N	O
Complications	NNS	complications	complication	complic	N	O
:	:	:	:	:	N	O
infrequent	NN	infrequent	infrequent	infrequ	N	O
:	:	:	:	:	N	O
fall	NN	fall	fall	fall	Y	B-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
infrequent	NN	infrequent	infrequent	infrequ	N	O
:	:	:	:	:	N	O
photosensitivity	NN	photosensitivity	photosensitivity	photosensit	Y	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
infrequent	NN	infrequent	infrequent	infrequ	N	O
:	:	:	:	:	N	O
enuresis	NN	enuresis	enuresis	enuresi	Y	B-AdverseReaction

6.2	CD	6.2	6.2	6.2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
many	JJ	many	many	mani	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Application	NNP	application	application	applic	N	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
primarily	RB	primarily	primarily	primarili	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
sublingual	JJ	sublingual	sublingual	sublingu	N	I-AdverseReaction
area	NN	area	area	area	N	I-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
application	NN	application	application	applic	N	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
included	VBD	included	included	includ	N	O
oral	JJ	oral	oral	oral	N	I-AdverseReaction
ulcers	NNS	ulcers	ulcer	ulcer	N	I-AdverseReaction
,	,	,	,	,	N	O
blisters	NNS	blisters	blister	blister	Y	I-AdverseReaction
,	,	,	,	,	N	O
peeling	VBG	peeling	peeling	peel	Y	I-AdverseReaction
sloughing	NN	sloughing	sloughing	slough	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
inflammation	NN	inflammation	inflammation	inflamm	Y	I-AdverseReaction
.	.	.	.	.	N	O

Choking	NN	choking	choking	choke	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
whom	WP	whom	whom	whom	N	O
may	MD	may	may	may	N	B-Factor
have	VB	have	have	have	N	O
also	RB	also	also	also	N	O
experienced	VBN	experienced	experienced	experienc	N	O
oropharyngeal	JJ	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
muscular	JJ	muscular	muscular	muscular	N	I-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
or	CC	or	or	or	N	O
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	B-AdverseReaction
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
INCREASED	NNP	increased	increased	increas	N	B-AdverseReaction
MORTALITY	NNP	mortality	mortality	mortal	N	I-AdverseReaction
IN	NNP	in	in	in	N	O
ELDERLY	NNP	elderly	elderly	elderli	Y	O
PATIENTS	NNP	patients	patient	patient	N	O
WITH	NNP	with	with	with	N	O
DEMENTIA	NNP	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
RELATED	JJ	related	related	relat	N	O
PSYCHOSIS	NNP	psychosis	psychosis	psychosi	Y	O
\n\n\n\n	NN	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
INCREASED	NNP	increased	increased	increas	N	B-AdverseReaction
MORTALITY	NNP	mortality	mortality	mortal	N	I-AdverseReaction
IN	NNP	in	in	in	N	O
ELDERLY	NNP	elderly	elderly	elderli	Y	O
PATIENTS	NNP	patients	patient	patient	N	O
WITH	NNP	with	with	with	N	O
DEMENTIA	NNP	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
RELATED	JJ	related	related	relat	N	O
PSYCHOSIS	NNP	psychosis	psychosis	psychosi	Y	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
Elderly	NNP	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	JJ	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	B-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

SAPHRIS	NNP	saphris	saphris	saphri	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)\n\n	NNP	)\n\n	)\n\n	)\n\n	N	O
(	(	(	(	(	N	O
asenapine	NN	asenapine	asenapine	asenapin	N	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
approved	VBN	approved	approved	approv	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	JJ	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
INCREASED	NNP	increased	increased	increas	N	B-AdverseReaction
MORTALITY	NNP	mortality	mortality	mortal	N	I-AdverseReaction
IN	NNP	in	in	in	N	O
ELDERLY	NNP	elderly	elderly	elderli	Y	O
PATIENTS	NNP	patients	patient	patient	N	O
WITH	NNP	with	with	with	N	O
DEMENTIA	NNP	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
RELATED	JJ	related	related	relat	N	O
PSYCHOSIS	NNP	psychosis	psychosis	psychosi	Y	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	JJ	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	B-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

SAPHRIS	NNP	saphris	saphris	saphri	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
approved	VBN	approved	approved	approv	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	JJ	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	B-AdverseReaction
Adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
Events	NNS	events	event	event	N	I-AdverseReaction
:	:	:	:	:	N	O
An	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
stroke	VBD	stroke	stroke	stroke	Y	B-AdverseReaction
,	,	,	,	,	N	O
transient	JJ	transient	transient	transient	N	B-AdverseReaction
ischemic	JJ	ischemic	ischemic	ischem	N	I-AdverseReaction
attack	NN	attack	attack	attack	N	I-AdverseReaction
)	)	)	)	)	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	JJ	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychoses	NNS	psychoses	psychosis	psychos	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	B-DrugClass
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	I-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Neuroleptic	JJ	neuroleptic	neuroleptic	neurolept	N	B-AdverseReaction
Malignant	NNP	malignant	malignant	malign	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
:	:	:	:	:	N	O
Manage	NN	manage	manage	manag	N	O
with	IN	with	with	with	N	O
immediate	JJ	immediate	immediate	immedi	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
and	CC	and	and	and	N	O
close	JJ	close	close	close	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Tardive	JJ	tardive	tardive	tardiv	N	B-AdverseReaction
Dyskinesia	NN	dyskinesia	dyskinesia	dyskinesia	Y	I-AdverseReaction
:	:	:	:	:	N	O
Discontinue	NN	discontinue	discontinue	discontinu	N	O
if	IN	if	if	if	N	O
clinically	RB	clinically	clinically	clinic	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

dispatch	NN	dispatch	dispatch	dispatch	N	O
:	:	:	:	:	N	O
unexpected	JJ	unexpected	unexpected	unexpect	N	O
key	NN	key	key	key	N	O
:	:	:	:	:	N	O
list	NN	list	list	list	N	O
in	IN	in	in	in	N	O
dispatch	NN	dispatch	dispatch	dispatch	N	O
table	NN	table	table	tabl	N	O
:	:	:	:	:	N	O
caption	NN	caption	caption	caption	N	O
:	:	:	:	:	N	O
function	NN	function	function	function	N	O
print_caption	NN	print_caption	print_caption	print_capt	N	O
at	IN	at	at	at	N	O
0	CD	0	0	0	N	O
x1c6c8c0	NN	x1c6c8c0	x1c6c8c0	x1c6c8c0	N	O
,	,	,	,	,	N	O
text	NN	text	text	text	N	O
:	:	:	:	:	N	O
function	NN	function	function	function	N	O
print_text	NN	print_text	print_text	print_text	N	O
at	IN	at	at	at	N	O
0	CD	0	0	0	N	O
x1c6c500	NN	x1c6c500	x1c6c500	x1c6c500	N	O

Metabolic	JJ	metabolic	metabolic	metabol	N	B-AdverseReaction
Changes	NNS	changes	change	chang	N	I-AdverseReaction
:	:	:	:	:	N	O
Atypical	NNP	atypical	atypical	atyp	N	B-DrugClass
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	I-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
metabolic	JJ	metabolic	metabolic	metabol	N	B-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	B-AdverseReaction
risk	NN	risk	risk	risk	N	I-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
metabolic	JJ	metabolic	metabolic	metabol	N	B-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
include	VBP	include	include	includ	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyslipidemia	NN	dyslipidemia	dyslipidemia	dyslipidemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
weight	VBD	weight	weight	weight	Y	B-AdverseReaction
gain	NN	gain	gain	gain	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Orthostatic	JJ	orthostatic	orthostatic	orthostat	N	B-AdverseReaction
Hypotension	NNP	hypotension	hypotension	hypotens	Y	I-AdverseReaction
,	,	,	,	,	N	O
Syncope	NNP	syncope	syncope	syncop	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Other	JJ	other	other	other	N	O
Hemodynamic	NNP	hemodynamic	hemodynamic	hemodynam	N	B-AdverseReaction
Effects	NNS	effects	effect	effect	N	I-AdverseReaction
:	:	:	:	:	N	O
Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
or	CC	or	or	or	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
early	JJ	early	early	earli	N	O
in	IN	in	in	in	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
known	JJ	known	known	known	N	O
cardiovascular	NN	cardiovascular	cardiovascular	cardiovascular	N	O
or	CC	or	or	or	N	O
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Leukopenia	NNP	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Agranulocytosis	NNP	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	B-DrugClass
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
low	JJ	low	low	low	N	O
white	JJ	white	white	white	N	O
blood	NN	blood	blood	blood	N	O
cell	NN	cell	cell	cell	N	O
count	NN	count	count	count	N	O
(	(	(	(	(	N	O
WBC	NNP	wbc	wbc	wbc	Y	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
should	MD	should	should	should	N	O
have	VB	have	have	have	N	O
their	PRP$	their	their	their	N	O
complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
count	NN	count	count	count	N	O
(	(	(	(	(	N	O
CBC	NNP	cbc	cbc	cbc	Y	O
)	)	)	)	)	N	O
monitored	VBD	monitored	monitored	monitor	N	O
frequently	RB	frequently	frequently	frequent	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
few	JJ	few	few	few	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
sign	NN	sign	sign	sign	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
decline	NN	decline	decline	declin	N	O
in	IN	in	in	in	N	O
WBC	NNP	wbc	wbc	wbc	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
causative	JJ	causative	causative	caus	N	O
factors	NNS	factors	factor	factor	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

QT	JJ	qt	qt	qt	N	B-AdverseReaction
Prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
:	:	:	:	:	N	O
Increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
QT	NNP	qt	qt	qt	N	I-AdverseReaction
interval	NN	interval	interval	interv	N	I-AdverseReaction
;	:	;	;	;	N	O
avoid	CC	avoid	avoid	avoid	N	O
use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
also	RB	also	also	also	N	O
increase	VBP	increase	increase	increas	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
prolonged	JJ	prolonged	prolonged	prolong	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O

Seizures	NNS	seizures	seizure	seizur	Y	B-AdverseReaction
:	:	:	:	:	N	O
Use	NNP	use	use	use	N	O
cautiously	RB	cautiously	cautiously	cautious	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
seizures	NNS	seizures	seizure	seizur	Y	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
lower	VBP	lower	lower	lower	N	O
the	DT	the	the	the	N	O
seizure	NN	seizure	seizure	seizur	Y	O
threshold	NN	threshold	threshold	threshold	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.11	CD	5.11	5.11	5.11	N	O
)	)	)	)	)	N	O

Potential	NNP	potential	potential	potenti	N	B-Factor
for	IN	for	for	for	N	O
Cognitive	NNP	cognitive	cognitive	cognit	N	B-AdverseReaction
and	CC	and	and	and	N	O
Motor	NNP	motor	motor	motor	N	B-AdverseReaction
Impairment	NNP	impairment	impairment	impair	N	I-AdverseReaction
:	:	:	:	:	N	O
Use	NNP	use	use	use	N	O
caution	NN	caution	caution	caution	N	O
when	WRB	when	when	when	N	O
operating	VBG	operating	operating	oper	N	O
machinery	NN	machinery	machinery	machineri	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.12	CD	5.12	5.12	5.12	N	O
)	)	)	)	)	N	O

Suicide	NN	suicide	suicide	suicid	Y	B-AdverseReaction
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
possibility	NN	possibility	possibility	possibl	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
suicide	JJ	suicide	suicide	suicid	Y	O
attempt	NN	attempt	attempt	attempt	N	O
is	VBZ	is	is	is	N	O
inherent	JJ	inherent	inherent	inher	N	O
in	IN	in	in	in	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
and	CC	and	and	and	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
disorder	NN	disorder	disorder	disord	N	O
.	.	.	.	.	N	O

Closely	RB	closely	closely	close	N	O
supervise	JJ	supervise	supervise	supervis	N	O
high	JJ	high	high	high	N	O
-	:	-	-	-	N	O
risk	NN	risk	risk	risk	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.14	CD	5.14	5.14	5.14	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Increased	VBN	increased	increased	increas	N	O
Mortality	NN	mortality	mortality	mortal	N	O
in	IN	in	in	in	N	O
Elderly	JJ	elderly	elderly	elderli	Y	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Dementia	NNP	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
Related	JJ	related	related	relat	N	O
Psychosis	NN	psychosis	psychosis	psychosi	Y	O

Elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	JJ	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	B-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

Analyses	NNS	analyses	analysis	analys	N	O
of	IN	of	of	of	N	O
17	CD	17	17	17	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
modal	JJ	modal	modal	modal	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
10	CD	10	10	10	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
largely	RB	largely	largely	larg	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
atypical	JJ	atypical	atypical	atyp	N	B-DrugClass
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	I-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
,	,	,	,	,	N	O
revealed	VBD	revealed	revealed	reveal	N	O
a	DT	a	a	a	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
of	IN	of	of	of	N	O
between	IN	between	between	between	N	O
1.6	CD	1.6	1.6	1.6	N	O
to	TO	to	to	to	N	O
1.7	CD	1.7	1.7	1.7	N	O
times	NNS	times	time	time	N	O
that	WDT	that	that	that	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
placebo	JJ	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Over	IN	over	over	over	N	O
the	DT	the	the	the	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
typical	JJ	typical	typical	typic	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
in	IN	in	in	in	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
was	VBD	was	wa	wa	N	O
about	IN	about	about	about	N	O
4.5%	CD	4.5%	4.5%	4.5%	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
about	IN	about	about	about	N	O
2.6%	CD	2.6%	2.6%	2.6%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Although	IN	although	although	although	N	O
the	DT	the	the	the	N	O
causes	NNS	causes	cause	caus	N	O
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
varied	VBN	varied	varied	vari	N	O
,	,	,	,	,	N	O
most	JJS	most	most	most	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
appeared	VBD	appeared	appeared	appear	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
either	RB	either	either	either	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
heart	NN	heart	heart	heart	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
sudden	JJ	sudden	sudden	sudden	N	B-AdverseReaction
death	NN	death	death	death	Y	I-AdverseReaction
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
infectious	JJ	infectious	infectious	infecti	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
nature	NN	nature	nature	natur	N	O
.	.	.	.	.	N	O

Observational	JJ	observational	observational	observ	N	O
studies	NNS	studies	study	studi	N	O
suggest	VBP	suggest	suggest	suggest	N	O
that	IN	that	that	that	N	O
,	,	,	,	,	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drugs	NNS	drugs	drug	drug	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
conventional	JJ	conventional	conventional	convent	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drugs	NNS	drugs	drug	drug	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
mortality	NN	mortality	mortality	mortal	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
extent	NN	extent	extent	extent	N	O
to	TO	to	to	to	N	O
which	WDT	which	which	which	N	O
the	DT	the	the	the	N	O
findings	NNS	findings	finding	find	N	O
of	IN	of	of	of	N	O
increased	JJ	increased	increased	increas	N	B-AdverseReaction
mortality	NN	mortality	mortality	mortal	N	I-AdverseReaction
in	IN	in	in	in	N	O
observational	JJ	observational	observational	observ	N	O
studies	NNS	studies	study	studi	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
attributed	VBN	attributed	attributed	attribut	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	B-DrugClass
drug	NN	drug	drug	drug	N	I-DrugClass
as	IN	as	a	as	N	O
opposed	VBN	opposed	opposed	oppos	N	O
to	TO	to	to	to	N	O
some	DT	some	some	some	N	O
characteristic	JJ	characteristic	characteristic	characterist	N	O
(	(	(	(	(	N	O
s	JJ	s	s	s	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
clear	JJ	clear	clear	clear	N	O
.	.	.	.	.	N	O

SAPHRIS	NNP	saphris	saphris	saphri	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
approved	VBN	approved	approved	approv	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	JJ	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	O
[	NNP	[	[	[	N	O
seeBoxed	VBD	seeboxed	seeboxed	seebox	N	O
Warningand	NNP	warningand	warningand	warningand	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Events	NNS	events	event	event	N	O
,	,	,	,	,	N	O
Including	VBG	including	including	includ	N	O
Stroke	NNP	stroke	stroke	stroke	Y	O
,	,	,	,	,	N	O
In	IN	in	in	in	N	O
Elderly	JJ	elderly	elderly	elderli	Y	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Dementia	NNP	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
Related	JJ	related	related	relat	N	O
Psychosis	NN	psychosis	psychosis	psychosi	Y	O

In	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
risperidone	NN	risperidone	risperidone	risperidon	N	B-DrugClass
,	,	,	,	,	N	O
aripiprazole	NN	aripiprazole	aripiprazole	aripiprazol	N	B-DrugClass
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
olanzapine	NN	olanzapine	olanzapine	olanzapin	N	B-DrugClass
in	IN	in	in	in	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
dementia	NN	dementia	dementia	dementia	Y	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	B-AdverseReaction
accidents	NNS	accidents	accident	accid	N	I-AdverseReaction
and	CC	and	and	and	N	O
transient	JJ	transient	transient	transient	N	B-AdverseReaction
ischemic	JJ	ischemic	ischemic	ischem	N	I-AdverseReaction
attacks	NNS	attacks	attack	attack	N	I-AdverseReaction
)	)	)	)	)	N	O
including	VBG	including	including	includ	N	O
fatalities	NNS	fatalities	fatality	fatal	N	B-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

SAPHRIS	NNP	saphris	saphris	saphri	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
approved	VBN	approved	approved	approv	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dementia	JJ	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
alsoBoxed	JJ	alsoboxed	alsoboxed	alsobox	N	O
Warningand	NNP	warningand	warningand	warningand	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Neuroleptic	JJ	neuroleptic	neuroleptic	neurolept	N	O
Malignant	NNP	malignant	malignant	malign	N	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

A	DT	a	a	a	N	O
potentially	RB	potentially	potentially	potenti	N	B-Factor
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
symptom	NN	symptom	symptom	symptom	N	O
complex	JJ	complex	complex	complex	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
referred	VBN	referred	referred	refer	N	O
to	TO	to	to	to	N	O
as	IN	as	a	as	N	O
Neuroleptic	NNP	neuroleptic	neuroleptic	neurolept	N	B-AdverseReaction
Malignant	NNP	malignant	malignant	malign	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
NMS	NNP	nms	nm	nm	N	B-AdverseReaction
)	)	)	)	)	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drugs	NNS	drugs	drug	drug	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
.	.	.	.	.	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
manifestations	NNS	manifestations	manifestation	manifest	N	O
of	IN	of	of	of	N	O
NMS	NNP	nms	nm	nm	N	B-AdverseReaction
are	VBP	are	are	are	N	O
hyperpyrexia	JJ	hyperpyrexia	hyperpyrexia	hyperpyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
rigidity	NN	rigidity	rigidity	rigid	Y	I-AdverseReaction
,	,	,	,	,	N	O
altered	VBD	altered	altered	alter	N	B-AdverseReaction
mental	JJ	mental	mental	mental	N	I-AdverseReaction
status	NN	status	status	statu	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
autonomic	JJ	autonomic	autonomic	autonom	N	B-AdverseReaction
instability	NN	instability	instability	instabl	N	I-AdverseReaction
(	(	(	(	(	N	O
irregular	JJ	irregular	irregular	irregular	N	B-AdverseReaction
pulse	NN	pulse	pulse	puls	N	I-AdverseReaction
or	CC	or	or	or	N	O
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
diaphoresis	NN	diaphoresis	diaphoresis	diaphoresi	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
dysrhythmia	NN	dysrhythmia	dysrhythmia	dysrhythmia	N	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Additional	JJ	additional	additional	addit	N	O
signs	NNS	signs	sign	sign	N	O
may	MD	may	may	may	N	B-Factor
include	VB	include	include	includ	N	O
elevated	JJ	elevated	elevated	elev	N	B-AdverseReaction
creatine	JJ	creatine	creatine	creatin	Y	I-AdverseReaction
phosphokinase	NN	phosphokinase	phosphokinase	phosphokinas	N	I-AdverseReaction
,	,	,	,	,	N	O
myoglobinuria	NN	myoglobinuria	myoglobinuria	myoglobinuria	Y	B-AdverseReaction
(	(	(	(	(	N	O
rhabdomyolysis	NN	rhabdomyolysis	rhabdomyolysis	rhabdomyolysi	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
diagnostic	JJ	diagnostic	diagnostic	diagnost	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
this	DT	this	this	thi	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
is	VBZ	is	is	is	N	O
complicated	VBN	complicated	complicated	complic	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
important	JJ	important	important	import	N	O
to	TO	to	to	to	N	O
exclude	VB	exclude	exclude	exclud	N	O
cases	NNS	cases	case	case	N	O
where	WRB	where	where	where	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
presentation	NN	presentation	presentation	present	N	O
includes	VBZ	includes	includes	includ	N	O
both	DT	both	both	both	N	O
serious	JJ	serious	serious	seriou	N	O
medical	JJ	medical	medical	medic	N	O
illness	NN	illness	illness	ill	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O

pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	O
,	,	,	,	,	N	O
systemic	JJ	systemic	systemic	system	N	O
infection	NN	infection	infection	infect	Y	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
untreated	JJ	untreated	untreated	untreat	N	O
or	CC	or	or	or	N	O
inadequately	RB	inadequately	inadequately	inadequ	N	O
treated	JJ	treated	treated	treat	N	O
extrapyramidal	JJ	extrapyramidal	extrapyramidal	extrapyramid	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
(	(	(	(	(	N	O
EPS	NNP	eps	eps	ep	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
important	JJ	important	important	import	N	O
considerations	NNS	considerations	consideration	consider	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
differential	JJ	differential	differential	differenti	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
include	VBP	include	include	includ	N	O
central	JJ	central	central	central	N	O
anticholinergic	JJ	anticholinergic	anticholinergic	anticholinerg	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
,	,	,	,	,	N	O
heat	NN	heat	heat	heat	N	O
stroke	NN	stroke	stroke	stroke	Y	O
,	,	,	,	,	N	O
drug	NN	drug	drug	drug	N	O
fever	NN	fever	fever	fever	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
primary	JJ	primary	primary	primari	N	O
central	JJ	central	central	central	N	O
nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
pathology	NN	pathology	pathology	patholog	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
NMS	NNP	nms	nm	nm	N	O
should	MD	should	should	should	N	O
include	VB	include	include	includ	N	O
:	:	:	:	:	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
immediate	JJ	immediate	immediate	immedi	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drugs	NNS	drugs	drug	drug	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
not	RB	not	not	not	N	O
essential	JJ	essential	essential	essenti	N	O
to	TO	to	to	to	N	O
concurrent	JJ	concurrent	concurrent	concurr	N	O
therapy	NN	therapy	therapy	therapi	N	O
;	:	;	;	;	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
intensive	JJ	intensive	intensive	intens	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
medical	JJ	medical	medical	medic	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
serious	JJ	serious	serious	seriou	N	O
medical	JJ	medical	medical	medic	N	O
problems	NNS	problems	problem	problem	N	O
for	IN	for	for	for	N	O
which	WDT	which	which	which	N	O
specific	JJ	specific	specific	specif	N	O
treatments	NNS	treatments	treatment	treatment	N	O
are	VBP	are	are	are	N	O
available	JJ	available	available	avail	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
no	DT	no	no	no	N	O
general	JJ	general	general	gener	N	O
agreement	NN	agreement	agreement	agreement	N	O
about	IN	about	about	about	N	O
specific	JJ	specific	specific	specif	N	O
pharmacological	JJ	pharmacological	pharmacological	pharmacolog	N	O
treatment	NN	treatment	treatment	treatment	N	O
regimens	NNS	regimens	regimen	regimen	N	O
for	IN	for	for	for	N	O
NMS	NNP	nms	nm	nm	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
requires	VBZ	requires	requires	requir	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drug	NN	drug	drug	drug	N	O
treatment	NN	treatment	treatment	treatment	N	O
after	IN	after	after	after	N	O
recovery	NN	recovery	recovery	recoveri	N	O
from	IN	from	from	from	N	O
NMS	NNP	nms	nm	nm	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
reintroduction	NN	reintroduction	reintroduction	reintroduct	N	O
of	IN	of	of	of	N	O
drug	NN	drug	drug	drug	N	O
therapy	NN	therapy	therapy	therapi	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
carefully	RB	carefully	carefully	care	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
carefully	RB	carefully	carefully	care	N	O
monitored	VBN	monitored	monitored	monitor	N	O
,	,	,	,	,	N	O
since	IN	since	since	sinc	N	O
recurrences	NNS	recurrences	recurrence	recurr	N	O
of	IN	of	of	of	N	O
NMS	NNP	nms	nm	nm	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Tardive	JJ	tardive	tardive	tardiv	N	O
Dyskinesia	NN	dyskinesia	dyskinesia	dyskinesia	Y	O

A	DT	a	a	a	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
of	IN	of	of	of	N	O
potentially	RB	potentially	potentially	potenti	N	B-Severity
irreversible	JJ	irreversible	irreversible	irrevers	N	I-Severity
,	,	,	,	,	N	O
involuntary	JJ	involuntary	involuntary	involuntari	N	B-AdverseReaction
,	,	,	,	,	N	I-AdverseReaction
dyskinetic	JJ	dyskinetic	dyskinetic	dyskinet	N	I-AdverseReaction
movements	NNS	movements	movement	movement	N	I-AdverseReaction
can	MD	can	can	can	N	O
develop	VB	develop	develop	develop	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	B-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
.	.	.	.	.	N	O

Although	IN	although	although	although	N	O
the	DT	the	the	the	N	O
prevalence	NN	prevalence	prevalence	preval	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
appears	VBZ	appears	appears	appear	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
highest	JJS	highest	highest	highest	N	O
among	IN	among	among	among	N	O
the	DT	the	the	the	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
women	NNS	women	woman	women	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
impossible	JJ	impossible	impossible	imposs	N	O
to	TO	to	to	to	N	O
rely	VB	rely	rely	reli	N	O
upon	JJ	upon	upon	upon	N	O
prevalence	NN	prevalence	prevalence	preval	N	O
estimates	NNS	estimates	estimate	estim	N	O
to	TO	to	to	to	N	O
predict	VB	predict	predict	predict	N	O
,	,	,	,	,	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
inception	NN	inception	inception	incept	N	O
of	IN	of	of	of	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
patients	NNS	patients	patient	patient	N	O
are	VBP	are	are	are	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
develop	VB	develop	develop	develop	N	O
the	DT	the	the	the	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
.	.	.	.	.	N	O

Whether	NNP	whether	whether	whether	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	B-DrugClass
drug	NN	drug	drug	drug	N	I-DrugClass
products	NNS	products	product	product	N	O
differ	VBP	differ	differ	differ	N	O
in	IN	in	in	in	N	O
their	PRP$	their	their	their	N	O
potential	JJ	potential	potential	potenti	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
Tardive	JJ	tardive	tardive	tardiv	N	B-AdverseReaction
Dyskinesia	NNP	dyskinesia	dyskinesia	dyskinesia	Y	I-AdverseReaction
(	(	(	(	(	N	O
TD	NNP	td	td	td	N	B-AdverseReaction
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
TD	NNP	td	td	td	N	B-AdverseReaction
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
likelihood	NN	likelihood	likelihood	likelihood	N	O
that	IN	that	that	that	N	O
it	PRP	it	it	it	N	O
will	MD	will	will	will	N	O
become	VB	become	become	becom	N	O
irreversible	JJ	irreversible	irreversible	irrevers	N	B-Severity
are	VBP	are	are	are	N	O
believed	VBN	believed	believed	believ	N	O
to	TO	to	to	to	N	O
increase	VB	increase	increase	increas	N	O
as	IN	as	a	as	N	O
the	DT	the	the	the	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
total	JJ	total	total	total	N	O
cumulative	JJ	cumulative	cumulative	cumul	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	B-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
patient	JJ	patient	patient	patient	N	O
increase	NN	increase	increase	increas	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
can	MD	can	can	can	N	O
develop	VB	develop	develop	develop	N	O
,	,	,	,	,	N	O
although	IN	although	although	although	N	O
much	JJ	much	much	much	N	O
less	JJR	less	le	less	N	O
commonly	RB	commonly	commonly	commonli	N	O
,	,	,	,	,	N	O
after	IN	after	after	after	N	O
relatively	RB	relatively	relatively	rel	N	O
brief	JJ	brief	brief	brief	N	O
treatment	NN	treatment	treatment	treatment	N	O
periods	NNS	periods	period	period	N	O
at	IN	at	at	at	N	O
low	JJ	low	low	low	N	O
doses	NNS	doses	dos	dose	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
no	DT	no	no	no	N	O
known	JJ	known	known	known	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
established	VBN	established	established	establish	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
TD	NNP	td	td	td	N	O
,	,	,	,	,	N	O
although	IN	although	although	although	N	O
the	DT	the	the	the	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
may	MD	may	may	may	N	O
remit	VB	remit	remit	remit	N	O
,	,	,	,	,	N	O
partially	RB	partially	partially	partial	N	O
or	CC	or	or	or	N	O
completely	RB	completely	completely	complet	N	O
,	,	,	,	,	N	O
if	IN	if	if	if	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
treatment	NN	treatment	treatment	treatment	N	O
is	VBZ	is	is	is	N	O
withdrawn	VBN	withdrawn	withdrawn	withdrawn	Y	O
.	.	.	.	.	N	O

Antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
itself	PRP	itself	itself	itself	N	O
,	,	,	,	,	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
may	MD	may	may	may	N	O
suppress	VB	suppress	suppress	suppress	N	O
(	(	(	(	(	N	O
or	CC	or	or	or	N	O
partially	RB	partially	partially	partial	N	O
suppress	JJ	suppress	suppress	suppress	N	O
)	)	)	)	)	N	O
the	DT	the	the	the	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
and	CC	and	and	and	N	O
thereby	NN	thereby	thereby	therebi	N	O
may	MD	may	may	may	N	O
possibly	RB	possibly	possibly	possibl	N	O
mask	VB	mask	mask	mask	N	O
the	DT	the	the	the	N	O
underlying	JJ	underlying	underlying	underli	N	O
process	NN	process	process	process	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
effect	NN	effect	effect	effect	N	O
that	IN	that	that	that	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
suppression	NN	suppression	suppression	suppress	N	O
has	VBZ	has	ha	ha	N	O
upon	IN	upon	upon	upon	N	O
the	DT	the	the	the	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
course	NN	course	course	cours	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Given	VBN	given	given	given	N	O
these	DT	these	these	these	N	O
considerations	NNS	considerations	consideration	consider	N	O
,	,	,	,	,	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
prescribed	VBN	prescribed	prescribed	prescrib	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
manner	NN	manner	manner	manner	N	O
that	WDT	that	that	that	N	O
is	VBZ	is	is	is	N	O
most	RBS	most	most	most	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
minimize	VB	minimize	minimize	minim	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
TD	NNP	td	td	td	N	O
.	.	.	.	.	N	O

Chronic	NNP	chronic	chronic	chronic	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
treatment	NN	treatment	treatment	treatment	N	O
should	MD	should	should	should	N	O
generally	RB	generally	generally	gener	N	O
be	VB	be	be	be	N	O
reserved	VBN	reserved	reserved	reserv	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
suffer	VBP	suffer	suffer	suffer	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
chronic	JJ	chronic	chronic	chronic	N	O
illness	NN	illness	illness	ill	N	O
that	WDT	that	that	that	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
respond	VB	respond	respond	respond	N	O
to	TO	to	to	to	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drugs	NNS	drugs	drug	drug	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
whom	WP	whom	whom	whom	N	O
alternative	JJ	alternative	alternative	altern	N	O
,	,	,	,	,	N	O
equally	RB	equally	equally	equal	N	O
effective	JJ	effective	effective	effect	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
potentially	RB	potentially	potentially	potenti	N	O
less	JJR	less	le	less	N	O
harmful	JJ	harmful	harmful	harm	N	O
treatments	NNS	treatments	treatment	treatment	N	O
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
available	JJ	available	available	avail	N	O
or	CC	or	or	or	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
do	VBP	do	do	do	N	O
require	VB	require	require	requir	N	O
chronic	JJ	chronic	chronic	chronic	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
smallest	JJS	smallest	smallest	smallest	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
shortest	JJS	shortest	shortest	shortest	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
producing	VBG	producing	producing	produc	N	O
a	DT	a	a	a	N	O
satisfactory	JJ	satisfactory	satisfactory	satisfactori	N	O
clinical	JJ	clinical	clinical	clinic	N	O
response	NN	response	response	respons	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
sought	VBN	sought	sought	sought	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
need	NN	need	need	need	N	O
for	IN	for	for	for	N	O
continued	JJ	continued	continued	continu	N	O
treatment	NN	treatment	treatment	treatment	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
reassessed	VBN	reassessed	reassessed	reassess	N	O
periodically	RB	periodically	periodically	period	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
TD	NNP	td	td	td	N	O
appear	VBP	appear	appear	appear	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
on	IN	on	on	on	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
,	,	,	,	,	N	O
drug	NN	drug	drug	drug	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
despite	IN	despite	despite	despit	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Metabolic	NNP	metabolic	metabolic	metabol	N	O
Changes	NNS	changes	change	chang	N	O

Atypical	NNP	atypical	atypical	atyp	N	B-DrugClass
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	I-DrugClass
drugs	NNS	drugs	drug	drug	N	I-DrugClass
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
metabolic	JJ	metabolic	metabolic	metabol	N	B-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	B-AdverseReaction
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	I-AdverseReaction
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	I-AdverseReaction
risk	NN	risk	risk	risk	N	I-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
metabolic	JJ	metabolic	metabolic	metabol	N	B-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
include	VBP	include	include	includ	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyslipidemia	NN	dyslipidemia	dyslipidemia	dyslipidemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
body	NN	body	body	bodi	N	B-AdverseReaction
weight	JJ	weight	weight	weight	Y	I-AdverseReaction
gain	NN	gain	gain	gain	N	I-AdverseReaction
.	.	.	.	.	N	O

While	IN	while	while	while	N	O
all	DT	all	all	all	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
drugs	NNS	drugs	drug	drug	N	B-DrugClass
in	IN	in	in	in	N	I-DrugClass
the	DT	the	the	the	N	I-DrugClass
class	NN	class	class	class	N	I-DrugClass
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
shown	VBN	shown	shown	shown	N	O
to	TO	to	to	to	N	O
produce	VB	produce	produce	produc	N	O
some	DT	some	some	some	N	O
metabolic	JJ	metabolic	metabolic	metabol	N	B-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
,	,	,	,	,	N	O
each	DT	each	each	each	N	O
drug	NN	drug	drug	drug	N	O
has	VBZ	has	ha	ha	N	O
its	PRP$	its	it	it	N	O
own	JJ	own	own	own	N	O
specific	JJ	specific	specific	specif	N	O
risk	NN	risk	risk	risk	N	O
profile	NN	profile	profile	profil	N	O
.	.	.	.	.	N	O

Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
and	CC	and	and	and	N	O
Diabetes	NNP	diabetes	diabetes	diabet	Y	O
Mellitus	NNP	mellitus	mellitus	mellitu	N	O

Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
cases	NNS	cases	case	case	N	O
extreme	JJ	extreme	extreme	extrem	N	B-Severity
and	CC	and	and	and	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
ketoacidosis	NN	ketoacidosis	ketoacidosis	ketoacidosi	Y	B-AdverseReaction
or	CC	or	or	or	N	O
hyperosmolar	JJ	hyperosmolar	hyperosmolar	hyperosmolar	N	B-AdverseReaction
coma	NN	coma	coma	coma	Y	I-AdverseReaction
or	CC	or	or	or	N	O
death	NN	death	death	death	Y	B-AdverseReaction
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	B-DrugClass
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	I-DrugClass
.	.	.	.	.	N	O

Assessment	NN	assessment	assessment	assess	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
relationship	NN	relationship	relationship	relationship	N	O
between	IN	between	between	between	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
use	NN	use	use	use	N	O
and	CC	and	and	and	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
is	VBZ	is	is	is	N	O
complicated	VBN	complicated	complicated	complic	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
possibility	NN	possibility	possibility	possibl	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
background	NN	background	background	background	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
mellitus	NNS	mellitus	mellitus	mellitu	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
increasing	VBG	increasing	increasing	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
mellitus	VBP	mellitus	mellitus	mellitu	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
general	JJ	general	general	gener	N	O
population	NN	population	population	popul	N	O
.	.	.	.	.	N	O

Given	VBN	given	given	given	N	O
these	DT	these	these	these	N	O
confounders	NNS	confounders	confounders	confound	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
relationship	NN	relationship	relationship	relationship	N	O
between	IN	between	between	between	N	O
atypical	JJ	atypical	atypical	atyp	N	B-DrugClass
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	I-DrugClass
use	NN	use	use	use	N	O
and	CC	and	and	and	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
completely	RB	completely	completely	complet	N	O
understood	JJ	understood	understood	understood	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
epidemiological	JJ	epidemiological	epidemiological	epidemiolog	N	O
studies	NNS	studies	study	studi	N	O
suggest	VBP	suggest	suggest	suggest	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	NN	emergent	emergent	emerg	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
atypical	JJ	atypical	atypical	atyp	N	B-DrugClass
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	I-DrugClass
included	VBD	included	included	includ	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

Precise	NNP	precise	precise	precis	N	O
risk	NN	risk	risk	risk	N	O
estimates	NNS	estimates	estimate	estim	N	O
for	IN	for	for	for	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	B-DrugClass
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	I-DrugClass
are	VBP	are	are	are	N	O
not	RB	not	not	not	N	O
available	JJ	available	available	avail	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
established	VBN	established	established	establish	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
mellitus	NNS	mellitus	mellitus	mellitu	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
started	VBN	started	started	start	N	O
on	IN	on	on	on	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
regularly	RB	regularly	regularly	regularli	N	O
for	IN	for	for	for	N	O
worsening	VBG	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
control	NN	control	control	control	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
mellitus	NNS	mellitus	mellitus	mellitu	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
obesity	NN	obesity	obesity	obes	Y	O
,	,	,	,	,	N	O
family	NN	family	family	famili	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
)	)	)	)	)	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
starting	VBG	starting	starting	start	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	O
should	MD	should	should	should	N	O
undergo	VB	undergo	undergo	undergo	N	O
fasting	VBG	fasting	fasting	fast	Y	O
blood	NN	blood	blood	blood	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
testing	VBG	testing	testing	test	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
beginning	NN	beginning	beginning	begin	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Any	DT	any	any	ani	N	O
patient	NN	patient	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
including	VBG	including	including	includ	N	O
polydipsia	NN	polydipsia	polydipsia	polydipsia	Y	O
,	,	,	,	,	N	O
polyuria	NN	polyuria	polyuria	polyuria	Y	O
,	,	,	,	,	N	O
polyphagia	NN	polyphagia	polyphagia	polyphagia	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
weakness	NN	weakness	weakness	weak	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	O
should	MD	should	should	should	N	O
undergo	VB	undergo	undergo	undergo	N	O
fasting	VBG	fasting	fasting	fast	Y	O
blood	NN	blood	blood	blood	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
testing	NN	testing	testing	test	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	O
has	VBZ	has	ha	ha	N	O
resolved	VBN	resolved	resolved	resolv	N	O
when	WRB	when	when	when	N	O
the	DT	the	the	the	N	O
atypical	JJ	atypical	atypical	atyp	N	O
antipsychotic	NN	antipsychotic	antipsychotic	antipsychot	N	O
was	VBD	was	wa	wa	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
required	VBN	required	required	requir	N	O
continuation	NN	continuation	continuation	continu	N	O
of	IN	of	of	of	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
diabetic	JJ	diabetic	diabetic	diabet	Y	O
treatment	NN	treatment	treatment	treatment	N	O
despite	IN	despite	despite	despit	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

Adult	NN	adult	adult	adult	N	O
Patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
Pooled	VBN	pooled	pooled	pool	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
and	CC	and	and	and	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

TABLE	NN	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
Fasting	VBG	fasting	fasting	fast	Y	O
Glucose	NNP	glucose	glucose	glucos	Y	O
in	IN	in	in	in	N	O
Adult	NNP	adult	adult	adult	N	O
Patients	NNS	patients	patient	patient	N	O

N	NNP	n	n	n	N	O
Number	NNP	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
assessments	NNS	assessments	assessment	assess	N	O
at	IN	at	at	at	N	O
both	DT	both	both	both	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
.	.	.	.	.	N	O

N	NNP	n	n	n	N	O
Number	NNP	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
at	IN	at	at	at	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
with	IN	with	with	with	N	O
assessments	NNS	assessments	assessment	assess	N	O
at	IN	at	at	at	N	O
both	DT	both	both	both	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
.	.	.	.	.	N	O

S	NNP	s	s	s	N	O
Includes	NNP	includes	includes	includ	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
90	CD	90	90	90	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
with	IN	with	with	with	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
dosing	NN	dosing	dosing	dose	N	O
.	.	.	.	.	N	O

Schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O

(	(	(	(	(	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Bipolar	NNP	bipolar	bipolar	bipolar	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
SAPHRIS5	NNP	saphris5	saphris5	saphris5	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mgtwice	NNS	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O

5	CD	5	5	5	N	O
mgtwice	JJ	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O
10	CD	10	10	10	N	O
mgtwice	JJ	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O
5	CD	5	5	5	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mgtwice	JJ	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O
S	NNP	s	s	s	N	O

Mean	JJ	mean	mean	mean	N	O
Change	NNP	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	O
Fasting	VBG	fasting	fasting	fast	Y	O
Glucose	NNP	glucose	glucose	glucos	Y	O
at	IN	at	at	at	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O

Change	NN	change	change	chang	N	O

from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
0.2	CD	0.2	0.2	0.2	N	O
(	(	(	(	(	N	O
232	CD	232	232	232	N	O
)	)	)	)	)	N	O
3.8	CD	3.8	3.8	3.8	N	O
(	(	(	(	(	N	O
158	CD	158	158	158	N	O
)	)	)	)	)	N	O
1.1	CD	1.1	1.1	1.1	N	O
(	(	(	(	(	N	O
153	CD	153	153	153	N	O
)	)	)	)	)	N	O
3.2	CD	3.2	3.2	3.2	N	O
(	(	(	(	(	N	O
377	CD	377	377	377	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
0.6	CD	0.6	0.6	0.6	N	O
(	(	(	(	(	N	O
89	CD	89	89	89	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
0.6	CD	0.6	0.6	0.6	N	O
(	(	(	(	(	N	O
156	CD	156	156	156	N	O
)	)	)	)	)	N	O

Proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Shifts	NNP	shifts	shift	shift	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
to	TO	to	to	to	N	O
Endpoint	VB	endpoint	endpoint	endpoint	N	O

Normal	NNP	normal	normal	normal	N	O
to	TO	to	to	to	N	O
High	NNP	high	high	high	N	O
100	CD	100	100	100	N	O
to	TO	to	to	to	N	O
126	CD	126	126	126	N	O
mg	NNS	mg	mg	mg	N	O
dL	VBD	dl	dl	dl	N	O
4.1%	CD	4.1%	4.1%	4.1%	N	O
4.5%	CD	4.5%	4.5%	4.5%	N	O
4.5%	CD	4.5%	4.5%	4.5%	N	O
5.0%	CD	5.0%	5.0%	5.0%	N	O
3.3%	CD	3.3%	3.3%	3.3%	N	O
2.7%	CD	2.7%	2.7%	2.7%	N	O

(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
170	CD	170	170	170	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
111	CD	111	111	111	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
111	CD	111	111	111	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
262	CD	262	262	262	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
61	CD	61	61	61	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
111	CD	111	111	111	N	O
)	)	)	)	)	N	O

Borderline	NNP	borderline	borderline	borderlin	N	O
to	TO	to	to	to	N	O
High	NNP	high	high	high	N	O
100	CD	100	100	100	N	O
and	CC	and	and	and	N	O
126	CD	126	126	126	N	O
to	TO	to	to	to	N	O
126	CD	126	126	126	N	O
mg	NNS	mg	mg	mg	N	O
dL	VBD	dl	dl	dl	N	O
5.9%	CD	5.9%	5.9%	5.9%	N	O
6.8%	CD	6.8%	6.8%	6.8%	N	O
6.3%	CD	6.3%	6.3%	6.3%	N	O
10.5%	CD	10.5%	10.5%	10.5%	N	O
0.0%	CD	0.0%	0.0%	0.0%	N	O
11.4%	CD	11.4%	11.4%	11.4%	N	O

(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
51	CD	51	51	51	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
44	CD	44	44	44	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
32	CD	32	32	32	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
95	CD	95	95	95	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
23	CD	23	23	23	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
35	CD	35	35	35	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
52	CD	52	52	52	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
comparator	NN	comparator	comparator	compar	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
that	WDT	that	that	that	N	O
included	VBD	included	included	includ	N	O
primarily	RB	primarily	primarily	primarili	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
of	IN	of	of	of	N	I-AdverseReaction
fasting	VBG	fasting	fasting	fast	Y	I-AdverseReaction
glucose	NN	glucose	glucose	glucos	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
2.4	CD	2.4	2.4	2.4	N	O
mg	JJ	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
.	.	.	.	.	N	O

Pediatric	JJ	pediatric	pediatric	pediatr	N	O

Patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
Data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
I	PRP	i	i	i	N	O
disorder	VBP	disorder	disorder	disord	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

TABLE	NN	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
Fasting	VBG	fasting	fasting	fast	Y	O
Glucose	NNP	glucose	glucose	glucos	Y	O
in	IN	in	in	in	N	O
Pediatric	NNP	pediatric	pediatric	pediatr	N	O
Subjects	NNS	subjects	subject	subject	N	O

Bipolar	JJ	bipolar	bipolar	bipolar	N	O
I	PRP	i	i	i	N	O
Disorder	NNP	disorder	disorder	disord	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
SAPHRIS2	NNP	saphris2	saphris2	saphris2	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
mgtwice	JJ	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O
SAPHRIS5	NNP	saphris5	saphris5	saphris5	N	O
mgtwice	NN	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O
SAPHRIS10	NNP	saphris10	saphris10	saphris10	N	O
mgtwice	NN	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O

Mean	JJ	mean	mean	mean	N	O
Change	NNP	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	O
Fasting	VBG	fasting	fasting	fast	Y	O
Glucose	NNP	glucose	glucose	glucos	Y	O
at	IN	at	at	at	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O

Change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
2.24	CD	2.24	2.24	2.24	N	O
(	(	(	(	(	N	O
56	CD	56	56	56	N	O
)	)	)	)	)	N	O
1.43	CD	1.43	1.43	1.43	N	O
(	(	(	(	(	N	O
51	CD	51	51	51	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
0.45	CD	0.45	0.45	0.45	N	O
(	(	(	(	(	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
0.34	CD	0.34	0.34	0.34	N	O
(	(	(	(	(	N	O
52	CD	52	52	52	N	O
)	)	)	)	)	N	O

Proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
Subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
Shifts	NNP	shifts	shift	shift	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
to	TO	to	to	to	N	O
Endpoint	VB	endpoint	endpoint	endpoint	N	O

Normal	NNP	normal	normal	normal	N	O
to	TO	to	to	to	N	O
High	NNP	high	high	high	N	O
45	CD	45	45	45	N	O
100	CD	100	100	100	N	O
to	TO	to	to	to	N	O
126	CD	126	126	126	N	O
mg	NNS	mg	mg	mg	N	O
dL	VBD	dl	dl	dl	N	O
0%	CD	0%	0%	0%	N	O
0%	CD	0%	0%	0%	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
0%	CD	0%	0%	0%	N	O

(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
56	CD	56	56	56	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
51	CD	51	51	51	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
52	CD	52	52	52	N	O
)	)	)	)	)	N	O

Dyslipidemia	NN	dyslipidemia	dyslipidemia	dyslipidemia	Y	B-AdverseReaction

Undesirable	JJ	undesirable	undesirable	undesir	N	B-AdverseReaction

alterations	NNS	alterations	alteration	alter	N	I-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
lipids	NNS	lipids	lipid	lipid	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
atypical	JJ	atypical	atypical	atyp	N	B-DrugClass
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	I-DrugClass
.	.	.	.	.	N	O

Adult	NN	adult	adult	adult	N	O
Patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
Pooled	VBN	pooled	pooled	pool	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
and	CC	and	and	and	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

TABLE	NN	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
Lipids	NNP	lipids	lipid	lipid	Y	O
in	IN	in	in	in	N	O
Adult	NNP	adult	adult	adult	N	O
Patients	NNS	patients	patient	patient	N	O

N	NNP	n	n	n	N	O
Number	NNP	number	number	number	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
assessments	NNS	assessments	assessment	assess	N	O
at	IN	at	at	at	N	O
both	DT	both	both	both	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
.	.	.	.	.	N	O

S	NNP	s	s	s	N	O
Includes	NNP	includes	includes	includ	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
90	CD	90	90	90	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
with	IN	with	with	with	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
dosing	NN	dosing	dosing	dose	N	O
.	.	.	.	.	N	O

Schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O

(	(	(	(	(	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Bipolar	NNP	bipolar	bipolar	bipolar	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
SAPHRIS5	NNP	saphris5	saphris5	saphris5	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mgtwice	NNS	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O

5	CD	5	5	5	N	O
mgtwice	JJ	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O
10	CD	10	10	10	N	O
mgtwice	JJ	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O
5	CD	5	5	5	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mgtwice	JJ	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O
S	NNP	s	s	s	N	O

Mean	JJ	mean	mean	mean	N	O
Change	NNP	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O

Total	JJ	total	total	total	N	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
2.2	CD	2.2	2.2	2.2	N	O
(	(	(	(	(	N	O
351	CD	351	351	351	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
2.4	CD	2.4	2.4	2.4	N	O
(	(	(	(	(	N	O
258	CD	258	258	258	N	O
)	)	)	)	)	N	O
3.3	CD	3.3	3.3	3.3	N	O
(	(	(	(	(	N	O
199	CD	199	199	199	N	O
)	)	)	)	)	N	O
0.4	CD	0.4	0.4	0.4	N	O
(	(	(	(	(	N	O
539	CD	539	539	539	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
1.5	CD	1.5	1.5	1.5	N	O
(	(	(	(	(	N	O
163	CD	163	163	163	N	O
)	)	)	)	)	N	O
1.1	CD	1.1	1.1	1.1	N	O
(	(	(	(	(	N	O
322	CD	322	322	322	N	O
)	)	)	)	)	N	O

LDL	NNP	ldl	ldl	ldl	Y	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
0.1	CD	0.1	0.1	0.1	N	O
(	(	(	(	(	N	O
285	CD	285	285	285	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
0.2	CD	0.2	0.2	0.2	N	O
(	(	(	(	(	N	O
195	CD	195	195	195	N	O
)	)	)	)	)	N	O
2.6	CD	2.6	2.6	2.6	N	O
(	(	(	(	(	N	O
195	CD	195	195	195	N	O
)	)	)	)	)	N	O
1.3	CD	1.3	1.3	1.3	N	O
(	(	(	(	(	N	O
465	CD	465	465	465	N	O
)	)	)	)	)	N	O
1.9	CD	1.9	1.9	1.9	N	O
(	(	(	(	(	N	O
158	CD	158	158	158	N	O
)	)	)	)	)	N	O
1.6	CD	1.6	1.6	1.6	N	O
(	(	(	(	(	N	O
304	CD	304	304	304	N	O
)	)	)	)	)	N	O

HDL	NNP	hdl	hdl	hdl	Y	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
0.5	CD	0.5	0.5	0.5	N	O
(	(	(	(	(	N	O
290	CD	290	290	290	N	O
)	)	)	)	)	N	O
0.4	CD	0.4	0.4	0.4	N	O
(	(	(	(	(	N	O
199	CD	199	199	199	N	O
)	)	)	)	)	N	O
1.0	CD	1.0	1.0	1.0	N	O
(	(	(	(	(	N	O
199	CD	199	199	199	N	O
)	)	)	)	)	N	O
0.5	CD	0.5	0.5	0.5	N	O
(	(	(	(	(	N	O
480	CD	480	480	480	N	O
)	)	)	)	)	N	O
0.0	CD	0.0	0.0	0.0	N	O
(	(	(	(	(	N	O
163	CD	163	163	163	N	O
)	)	)	)	)	N	O
0.9	CD	0.9	0.9	0.9	N	O
(	(	(	(	(	N	O
322	CD	322	322	322	N	O
)	)	)	)	)	N	O

Fasting	VBG	fasting	fasting	fast	Y	O
triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
7.6	CD	7.6	7.6	7.6	N	O
(	(	(	(	(	N	O
233	CD	233	233	233	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
1.9	CD	1.9	1.9	1.9	N	O
(	(	(	(	(	N	O
159	CD	159	159	159	N	O
)	)	)	)	)	N	O
0.1	CD	0.1	0.1	0.1	N	O
(	(	(	(	(	N	O
154	CD	154	154	154	N	O
)	)	)	)	)	N	O
3.8	CD	3.8	3.8	3.8	N	O
(	(	(	(	(	N	O
380	CD	380	380	380	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
17.9	CD	17.9	17.9	17.9	N	O
(	(	(	(	(	N	O
129	CD	129	129	129	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
3.5	CD	3.5	3.5	3.5	N	O
(	(	(	(	(	N	O
237	CD	237	237	237	N	O
)	)	)	)	)	N	O

Proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Shifts	NNP	shifts	shift	shift	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
to	TO	to	to	to	N	O
Endpoint	VB	endpoint	endpoint	endpoint	N	O

Total	JJ	total	total	total	N	O
cholesterolNormal	NN	cholesterolnormal	cholesterolnormal	cholesterolnorm	N	O
to	TO	to	to	to	N	O
High	NNP	high	high	high	N	O
200	CD	200	200	200	N	O
to	TO	to	to	to	N	O
240	CD	240	240	240	N	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
225	CD	225	225	225	N	O
)	)	)	)	)	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
161	CD	161	161	161	N	O
)	)	)	)	)	N	O
2.2%	CD	2.2%	2.2%	2.2%	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
134	CD	134	134	134	N	O
)	)	)	)	)	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
343	CD	343	343	343	N	O
)	)	)	)	)	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
95	CD	95	95	95	N	O
)	)	)	)	)	N	O
2.5%	CD	2.5%	2.5%	2.5%	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
204	CD	204	204	204	N	O
)	)	)	)	)	N	O

LDLNormal	NNP	ldlnormal	ldlnormal	ldlnormal	N	O
to	TO	to	to	to	N	O
High	NNP	high	high	high	N	O
100	CD	100	100	100	N	O
to	TO	to	to	to	N	O
160	CD	160	160	160	N	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
117	CD	117	117	117	N	O
)	)	)	)	)	N	O
0.0%	CD	0.0%	0.0%	0.0%	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
80	CD	80	80	80	N	O
)	)	)	)	)	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
86	CD	86	86	86	N	O
)	)	)	)	)	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
196	CD	196	196	196	N	O
)	)	)	)	)	N	O
1.9%	CD	1.9%	1.9%	1.9%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
53	CD	53	53	53	N	O
)	)	)	)	)	N	O
0.0%	CD	0.0%	0.0%	0.0%	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
141	CD	141	141	141	N	O
)	)	)	)	)	N	O

HDLNormal	NNP	hdlnormal	hdlnormal	hdlnormal	N	O
to	TO	to	to	to	N	O
Low	VB	low	low	low	N	O
40	CD	40	40	40	N	O
to	TO	to	to	to	N	O
40	CD	40	40	40	N	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
10.7%	CD	10.7%	10.7%	10.7%	N	O
(	(	(	(	(	N	O
21	CD	21	21	21	N	O
196	CD	196	196	196	N	O
)	)	)	)	)	N	O
13.3%	CD	13.3%	13.3%	13.3%	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
135	CD	135	135	135	N	O
)	)	)	)	)	N	O
14.7%	CD	14.7%	14.7%	14.7%	N	O
(	(	(	(	(	N	O
20	CD	20	20	20	N	O
136	CD	136	136	136	N	O
)	)	)	)	)	N	O
14.0%	CD	14.0%	14.0%	14.0%	N	O
(	(	(	(	(	N	O
45	CD	45	45	45	N	O
322	CD	322	322	322	N	O
)	)	)	)	)	N	O
7.4%	CD	7.4%	7.4%	7.4%	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
122	CD	122	122	122	N	O
)	)	)	)	)	N	O
8.7%	CD	8.7%	8.7%	8.7%	N	O
(	(	(	(	(	N	O
21	CD	21	21	21	N	O
242	CD	242	242	242	N	O
)	)	)	)	)	N	O

Fasting	VBG	fasting	fasting	fast	Y	O
triglyceridesNormal	NN	triglyceridesnormal	triglyceridesnormal	triglyceridesnorm	N	O
to	TO	to	to	to	N	O
High	NNP	high	high	high	N	O
150	CD	150	150	150	N	O
to	TO	to	to	to	N	O
200	CD	200	200	200	N	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
2.4%	CD	2.4%	2.4%	2.4%	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
167	CD	167	167	167	N	O
)	)	)	)	)	N	O
7.0%	CD	7.0%	7.0%	7.0%	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
115	CD	115	115	115	N	O
)	)	)	)	)	N	O
8.3%	CD	8.3%	8.3%	8.3%	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
108	CD	108	108	108	N	O
)	)	)	)	)	N	O
7.7%	CD	7.7%	7.7%	7.7%	N	O
(	(	(	(	(	N	O
20	CD	20	20	20	N	O
260	CD	260	260	260	N	O
)	)	)	)	)	N	O
5.1%	CD	5.1%	5.1%	5.1%	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
78	CD	78	78	78	N	O
)	)	)	)	)	N	O
7.4%	CD	7.4%	7.4%	7.4%	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
148	CD	148	148	148	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
total	JJ	total	total	total	N	B-AdverseReaction
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	I-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
240	CD	240	240	240	N	B-Severity
mg	NNS	mg	mg	mg	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
(	(	(	(	(	N	O
at	IN	at	at	at	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
8.3%	CD	8.3%	8.3%	8.3%	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
versus	VBP	versus	versus	versu	N	O
7%	CD	7%	7%	7%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	I-AdverseReaction
200	CD	200	200	200	N	B-Severity
mg	NNS	mg	mg	mg	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
(	(	(	(	(	N	O
at	IN	at	at	at	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
13.2%	CD	13.2%	13.2%	13.2%	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
versus	VBP	versus	versus	versu	N	O
10.5%	CD	10.5%	10.5%	10.5%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
total	JJ	total	total	total	N	B-AdverseReaction
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	I-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
240	CD	240	240	240	N	B-Severity
mg	NNS	mg	mg	mg	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
(	(	(	(	(	N	O
at	IN	at	at	at	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
8.7%	CD	8.7%	8.7%	8.7%	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
versus	VBP	versus	versus	versu	N	O
8.6%	CD	8.6%	8.6%	8.6%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	I-AdverseReaction
200	CD	200	200	200	N	B-Severity
mg	NNS	mg	mg	mg	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
(	(	(	(	(	N	O
at	IN	at	at	at	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
15.2%	CD	15.2%	15.2%	15.2%	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
versus	VBP	versus	versus	versu	N	O
11.4%	CD	11.4%	11.4%	11.4%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O

a	DT	a	a	a	N	O
52	CD	52	52	52	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
comparator	NN	comparator	comparator	compar	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
that	WDT	that	that	that	N	O
included	VBD	included	included	includ	N	O
primarily	RB	primarily	primarily	primarili	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
decrease	NN	decrease	decrease	decreas	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
of	IN	of	of	of	N	O
total	JJ	total	total	total	N	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O
was	VBD	was	wa	wa	N	O
6	CD	6	6	6	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
decrease	NN	decrease	decrease	decreas	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
of	IN	of	of	of	N	O
fasting	VBG	fasting	fasting	fast	Y	O
triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	O
was	VBD	was	wa	wa	N	O
9.8	CD	9.8	9.8	9.8	N	O
mg	JJ	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
.	.	.	.	.	N	O

Pediatric	JJ	pediatric	pediatric	pediatr	N	O
Patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
Data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
trial	NN	trial	trial	trial	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

TABLE	NN	table	table	tabl	N	O
4	CD	4	4	4	N	O
:	:	:	:	:	N	O
Changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
Fasting	VBG	fasting	fasting	fast	Y	O
Lipids	NNP	lipids	lipid	lipid	Y	O
in	IN	in	in	in	N	O
Pediatric	NNP	pediatric	pediatric	pediatr	N	O
Subjects	NNS	subjects	subject	subject	N	O

N	NNP	n	n	n	N	O
Number	NNP	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
assessments	NNS	assessments	assessment	assess	N	O
at	IN	at	at	at	N	O
both	DT	both	both	both	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O

Bipolar	JJ	bipolar	bipolar	bipolar	N	O

I	PRP	i	i	i	N	O
Disorder	NNP	disorder	disorder	disord	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
SAPHRIS2	NNP	saphris2	saphris2	saphris2	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
mgtwice	JJ	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O
SAPHRIS5	NNP	saphris5	saphris5	saphris5	N	O
mgtwice	NN	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O
SAPHRIS10	NNP	saphris10	saphris10	saphris10	N	O
mgtwice	NN	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O

Mean	JJ	mean	mean	mean	N	O
Change	NNP	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O

Total	JJ	total	total	total	N	O
fasting	NN	fasting	fasting	fast	Y	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
2.3	CD	2.3	2.3	2.3	N	O
(	(	(	(	(	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
3.7	CD	3.7	3.7	3.7	N	O
(	(	(	(	(	N	O
50	CD	50	50	50	N	O
)	)	)	)	)	N	O
7.2	CD	7.2	7.2	7.2	N	O
(	(	(	(	(	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
9.3	CD	9.3	9.3	9.3	N	O
(	(	(	(	(	N	O
52	CD	52	52	52	N	O
)	)	)	)	)	N	O

Fasting	VBG	fasting	fasting	fast	Y	O
LDL	NNP	ldl	ldl	ldl	Y	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
2.5	CD	2.5	2.5	2.5	N	O
(	(	(	(	(	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
0.2	CD	0.2	0.2	0.2	N	O
(	(	(	(	(	N	O
50	CD	50	50	50	N	O
)	)	)	)	)	N	O
3.0	CD	3.0	3.0	3.0	N	O
(	(	(	(	(	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
4.9	CD	4.9	4.9	4.9	N	O
(	(	(	(	(	N	O
51	CD	51	51	51	N	O
)	)	)	)	)	N	O

Fasting	VBG	fasting	fasting	fast	Y	O
HDL	NNP	hdl	hdl	hdl	Y	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
1.6	CD	1.6	1.6	1.6	N	O
(	(	(	(	(	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
2.3	CD	2.3	2.3	2.3	N	O
(	(	(	(	(	N	O
50	CD	50	50	50	N	O
)	)	)	)	)	N	O
1.5	CD	1.5	1.5	1.5	N	O
(	(	(	(	(	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
1.7	CD	1.7	1.7	1.7	N	O
(	(	(	(	(	N	O
52	CD	52	52	52	N	O
)	)	)	)	)	N	O

Fasting	VBG	fasting	fasting	fast	Y	O
triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
6.6	CD	6.6	6.6	6.6	N	O
(	(	(	(	(	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
8.7	CD	8.7	8.7	8.7	N	O
(	(	(	(	(	N	O
50	CD	50	50	50	N	O
)	)	)	)	)	N	O
13.4	CD	13.4	13.4	13.4	N	O
(	(	(	(	(	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
14.7	CD	14.7	14.7	14.7	N	O
(	(	(	(	(	N	O
52	CD	52	52	52	N	O
)	)	)	)	)	N	O

Proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
Subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
Shifts	NNP	shifts	shift	shift	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
to	TO	to	to	to	N	O
Endpoint	VB	endpoint	endpoint	endpoint	N	O

Total	JJ	total	total	total	N	O
fasting	VBG	fasting	fasting	fast	Y	O
cholesterolNormal	NN	cholesterolnormal	cholesterolnormal	cholesterolnorm	N	O
to	TO	to	to	to	N	O
High	NNP	high	high	high	N	O
170	CD	170	170	170	N	O
to	TO	to	to	to	N	O
200	CD	200	200	200	N	O
(	(	(	(	(	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)(	NNP	)(	)(	)(	N	O
n	RB	n	n	n	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
0%	CD	0%	0%	0%	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
50	CD	50	50	50	N	O
)	)	)	)	)	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
0%	CD	0%	0%	0%	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
52	CD	52	52	52	N	O
)	)	)	)	)	N	O

Fasting	VBG	fasting	fasting	fast	Y	O
LDLNormal	NNP	ldlnormal	ldlnormal	ldlnormal	N	O
to	TO	to	to	to	N	O
High	NNP	high	high	high	N	O
110	CD	110	110	110	N	O
to	TO	to	to	to	N	O
130	CD	130	130	130	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
50	CD	50	50	50	N	O
)	)	)	)	)	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
0%	CD	0%	0%	0%	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
51	CD	51	51	51	N	O
)	)	)	)	)	N	O

Fasting	VBG	fasting	fasting	fast	Y	O
HDLNormal	NNP	hdlnormal	hdlnormal	hdlnormal	N	O
to	TO	to	to	to	N	O
Low	VB	low	low	low	N	O
40	CD	40	40	40	N	O
to	TO	to	to	to	N	O
40	CD	40	40	40	N	O
(	(	(	(	(	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)(	NNP	)(	)(	)(	N	O
n	RB	n	n	n	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
3.5%	CD	3.5%	3.5%	3.5%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
6.0%	CD	6.0%	6.0%	6.0%	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
50	CD	50	50	50	N	O
)	)	)	)	)	N	O
3.5%	CD	3.5%	3.5%	3.5%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
9.6%	CD	9.6%	9.6%	9.6%	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
52	CD	52	52	52	N	O
)	)	)	)	)	N	O

Fasting	VBG	fasting	fasting	fast	Y	O
triglyceridesNormal	NN	triglyceridesnormal	triglyceridesnormal	triglyceridesnorm	N	O
to	TO	to	to	to	N	O
High	NNP	high	high	high	N	O
150	CD	150	150	150	N	O
to	TO	to	to	to	N	O
200	CD	200	200	200	N	O
(	(	(	(	(	N	O
mg	NN	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)(	NNP	)(	)(	)(	N	O
n	RB	n	n	n	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
0%	CD	0%	0%	0%	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
4.0%	CD	4.0%	4.0%	4.0%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
50	CD	50	50	50	N	O
)	)	)	)	)	N	O
3.5%	CD	3.5%	3.5%	3.5%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
1.9%	CD	1.9%	1.9%	1.9%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
52	CD	52	52	52	N	O
)	)	)	)	)	N	O

Weight	NNP	weight	weight	weight	Y	O
Gain	NNP	gain	gain	gain	N	O

Increases	NNS	increases	increase	increas	N	B-AdverseReaction

in	IN	in	in	in	N	I-AdverseReaction
weight	NN	weight	weight	weight	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
should	MD	should	should	should	N	O
receive	VB	receive	receive	receiv	N	O
regular	JJ	regular	regular	regular	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
weight	JJ	weight	weight	weight	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Patient	NNP	patient	patient	patient	N	O
Counseling	NNP	counseling	counseling	counsel	N	O
Information	NNP	information	information	inform	N	O
(	(	(	(	(	N	O
17	CD	17	17	17	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Adult	NN	adult	adult	adult	N	O
Patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
Pooled	VBN	pooled	pooled	pool	N	O
data	NNS	data	data	data	N	O
on	IN	on	on	on	N	O
mean	NN	mean	mean	mean	N	O
changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
body	NN	body	body	bodi	N	O
weight	NN	weight	weight	weight	Y	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
meeting	VBG	meeting	meeting	meet	N	O
a	DT	a	a	a	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
gain	NN	gain	gain	gain	N	I-AdverseReaction
criterion	NN	criterion	criterion	criterion	N	O
of	IN	of	of	of	N	O
7%	CD	7%	7%	7%	N	B-Severity
of	IN	of	of	of	N	O
body	NN	body	body	bodi	N	O
weight	NN	weight	weight	weight	Y	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
and	CC	and	and	and	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
:	:	:	:	:	N	O
Change	NN	change	change	chang	N	O
in	IN	in	in	in	N	O
Body	NNP	body	body	bodi	N	O
Weight	NNP	weight	weight	weight	Y	O
in	IN	in	in	in	N	O
Adult	NNP	adult	adult	adult	N	O
Patients	NNS	patients	patient	patient	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O

N	NNP	n	n	n	N	O
Number	NNP	number	number	number	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
assessments	NNS	assessments	assessment	assess	N	O
at	IN	at	at	at	N	O
both	DT	both	both	both	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
.	.	.	.	.	N	O

S	NNP	s	s	s	N	O
Includes	NNP	includes	includes	includ	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
90	CD	90	90	90	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
with	IN	with	with	with	N	O
flexible	JJ	flexible	flexible	flexibl	N	O
dosing	NN	dosing	dosing	dose	N	O
.	.	.	.	.	N	O

Schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O

(	(	(	(	(	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Bipolar	NNP	bipolar	bipolar	bipolar	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
SAPHRIS5	NNP	saphris5	saphris5	saphris5	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mgtwice	NNS	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O

5	CD	5	5	5	N	O
mgtwice	JJ	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O
10	CD	10	10	10	N	O
mgtwice	JJ	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O
5	CD	5	5	5	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mgtwice	JJ	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O
S	NNP	s	s	s	N	O

Change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
kg	NN	kg	kg	kg	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
0.0	CD	0.0	0.0	0.0	N	O
(	(	(	(	(	N	O
348	CD	348	348	348	N	O
)	)	)	)	)	N	O
1.0	CD	1.0	1.0	1.0	N	O
(	(	(	(	(	N	O
251	CD	251	251	251	N	O
)	)	)	)	)	N	O
0.9	CD	0.9	0.9	0.9	N	O
(	(	(	(	(	N	O
200	CD	200	200	200	N	O
)	)	)	)	)	N	O
1.1	CD	1.1	1.1	1.1	N	O
(	(	(	(	(	N	O
532	CD	532	532	532	N	O
)	)	)	)	)	N	O
0.2	CD	0.2	0.2	0.2	N	O
(	(	(	(	(	N	O
171	CD	171	171	171	N	O
)	)	)	)	)	N	O
1.3	CD	1.3	1.3	1.3	N	O
(	(	(	(	(	N	O
336	CD	336	336	336	N	O
)	)	)	)	)	N	O

Proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
7%	CD	7%	7%	7%	N	B-Severity
Increase	NNP	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Body	NNP	body	body	bodi	N	I-AdverseReaction
Weight	NNP	weight	weight	weight	Y	I-AdverseReaction

with	IN	with	with	with	N	O
7%	CD	7%	7%	7%	N	B-Severity
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
weight	VBD	weight	weight	weight	Y	I-AdverseReaction
1.6%	CD	1.6%	1.6%	1.6%	N	O
4.4%	CD	4.4%	4.4%	4.4%	N	O
4.8%	CD	4.8%	4.8%	4.8%	N	O
4.9%	CD	4.9%	4.9%	4.9%	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
5.8%	CD	5.8%	5.8%	5.8%	N	O

Adult	NN	adult	adult	adult	N	O
Patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
52	CD	52	52	52	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
comparator	NN	comparator	comparator	compar	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
adult	NN	adult	adult	adult	N	O
trial	NN	trial	trial	trial	N	O
that	WDT	that	that	that	N	O
included	VBD	included	included	includ	N	O
primarily	RB	primarily	primarily	primarili	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
gain	NN	gain	gain	gain	N	I-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
was	VBD	was	wa	wa	N	O
0.9	CD	0.9	0.9	0.9	N	O
kg	NN	kg	kg	kg	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
7%	CD	7%	7%	7%	N	B-Severity
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
weight	NN	weight	weight	weight	Y	I-AdverseReaction
(	(	(	(	(	N	O
at	IN	at	at	at	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
14.7%	CD	14.7%	14.7%	14.7%	N	O
.	.	.	.	.	N	O
Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
provides	VBZ	provides	provides	provid	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
change	NN	change	change	chang	N	I-AdverseReaction
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
weight	JJ	weight	weight	weight	Y	B-AdverseReaction
gain	NN	gain	gain	gain	N	I-AdverseReaction
of	IN	of	of	of	N	O
7%	CD	7%	7%	7%	N	B-Severity
categorized	VBN	categorized	categorized	categor	N	O
by	IN	by	by	by	N	O
Body	NNP	body	body	bodi	N	O
Mass	NNP	mass	mass	mass	Y	O
Index	NNP	index	index	index	N	O
(	(	(	(	(	N	O
BMI	NNP	bmi	bmi	bmi	N	O
)	)	)	)	)	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

6	CD	6	6	6	N	O
:	:	:	:	:	N	O
Weight	JJ	weight	weight	weight	Y	O
Change	NNP	change	change	chang	N	O
Results	NNP	results	result	result	N	O
Categorized	NNP	categorized	categorized	categor	N	O
by	IN	by	by	by	N	O
BMI	NNP	bmi	bmi	bmi	N	O
at	IN	at	at	at	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
:	:	:	:	:	N	O
Comparator	NNP	comparator	comparator	compar	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
52	CD	52	52	52	N	O
-	:	-	-	-	N	O
Week	NN	week	week	week	N	O
Study	NNP	study	study	studi	N	O
in	IN	in	in	in	N	O
Adults	NNP	adults	adult	adult	N	O
with	IN	with	with	with	N	O
Schizophrenia	NNP	schizophrenia	schizophrenia	schizophrenia	Y	O

BMI	NNP	bmi	bmi	bmi	N	O
23	CD	23	23	23	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
N	NNP	n	n	n	N	O
295	CD	295	295	295	N	O
BMI	NNP	bmi	bmi	bmi	N	O
23	CD	23	23	23	N	O
-	:	-	-	-	N	O
27	CD	27	27	27	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
N	NNP	n	n	n	N	O
290	CD	290	290	290	N	O
BMI	NNP	bmi	bmi	bmi	N	O
27	CD	27	27	27	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
N	NNP	n	n	n	N	O
302	CD	302	302	302	N	O

Mean	JJ	mean	mean	mean	N	O
change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
kg	NN	kg	kg	kg	N	O
)	)	)	)	)	N	O
1.7	CD	1.7	1.7	1.7	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

with	IN	with	with	with	N	O
7%	CD	7%	7%	7%	N	B-Severity
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
weight	VBD	weight	weight	weight	Y	I-AdverseReaction
22%	CD	22%	22%	22%	N	O
13%	CD	13%	13%	13%	N	O
9%	CD	9%	9%	9%	N	O

Pediatric	JJ	pediatric	pediatric	pediatr	N	O
Patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
Data	NNS	data	data	data	N	O
on	IN	on	on	on	N	O
mean	NN	mean	mean	mean	N	O
changes	NNS	changes	change	chang	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
weight	NN	weight	weight	weight	Y	I-AdverseReaction
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
meeting	VBG	meeting	meeting	meet	N	O
a	DT	a	a	a	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
gain	NN	gain	gain	gain	N	I-AdverseReaction
criterion	NN	criterion	criterion	criterion	N	O
of	IN	of	of	of	N	O
7%	CD	7%	7%	7%	N	B-Severity
of	IN	of	of	of	N	O
body	NN	body	body	bodi	N	O
weight	NN	weight	weight	weight	Y	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
trial	NN	trial	trial	trial	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
7	CD	7	7	7	N	O
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
adjust	VB	adjust	adjust	adjust	N	O
for	IN	for	for	for	N	O
normal	JJ	normal	normal	normal	N	O
growth	NN	growth	growth	growth	N	O
,	,	,	,	,	N	O
z	SYM	z	z	z	N	O
-	:	-	-	-	N	O
scores	NNS	scores	score	score	N	O
were	VBD	were	were	were	N	O
derived	VBN	derived	derived	deriv	N	O
(	(	(	(	(	N	O
measured	VBN	measured	measured	measur	N	O
in	IN	in	in	in	N	O
standard	JJ	standard	standard	standard	N	O
deviations	NNS	deviations	deviation	deviat	N	O
[	VBP	[	[	[	N	O
SD	NNP	sd	sd	sd	N	O
])	NNP	])	])	])	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
normalize	VBP	normalize	normalize	normal	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
natural	JJ	natural	natural	natur	N	O
growth	NN	growth	growth	growth	N	O
of	IN	of	of	of	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
by	IN	by	by	by	N	O
comparisons	NNS	comparisons	comparison	comparison	N	O
to	TO	to	to	to	N	O
age	NN	age	age	age	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
sex	NN	sex	sex	sex	N	O
-	:	-	-	-	N	O
matched	VBN	matched	matched	match	N	O
population	NN	population	population	popul	N	O
standards	NNS	standards	standard	standard	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O

distance	NN	distance	distance	distanc	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
z	NN	z	z	z	N	O
-	:	-	-	-	N	O
score	NN	score	score	score	N	O
from	IN	from	from	from	N	O
0	CD	0	0	0	N	O
represents	VBZ	represents	represents	repres	N	O
the	DT	the	the	the	N	O
distance	NN	distance	distance	distanc	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
percentile	NN	percentile	percentile	percentil	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
median	NN	median	median	median	N	O
,	,	,	,	,	N	O
measured	VBN	measured	measured	measur	N	O
in	IN	in	in	in	N	O
standard	JJ	standard	standard	standard	N	O
deviations	NNS	deviations	deviation	deviat	N	O
(	(	(	(	(	N	O
SD	NNP	sd	sd	sd	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

After	IN	after	after	after	N	O
adjusting	VBG	adjusting	adjusting	adjust	N	O
for	IN	for	for	for	N	O
age	NN	age	age	age	N	O
and	CC	and	and	and	N	O
sex	NN	sex	sex	sex	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
to	TO	to	to	to	N	O
endpoint	VB	endpoint	endpoint	endpoint	N	O
in	IN	in	in	in	N	O
weight	NN	weight	weight	weight	Y	O
z	SYM	z	z	z	N	O
-	:	-	-	-	N	O
score	NN	score	score	score	N	O
for	IN	for	for	for	N	O
SAPHRS	NNP	saphrs	saphrs	saphr	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
was	VBD	was	wa	wa	N	O
0.11	CD	0.11	0.11	0.11	N	O
,	,	,	,	,	N	O
0.08	CD	0.08	0.08	0.08	N	O
and	CC	and	and	and	N	O
0.09	CD	0.09	0.09	0.09	N	O
SD	NNP	sd	sd	sd	N	O
versus	NN	versus	versus	versu	N	O
0.02	CD	0.02	0.02	0.02	N	O
SD	NNP	sd	sd	sd	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
treating	VBG	treating	treating	treat	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
weight	VBD	weight	weight	weight	Y	O
gain	NN	gain	gain	gain	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
and	CC	and	and	and	N	O
assessed	VBN	assessed	assessed	assess	N	O
against	IN	against	against	against	N	O
that	DT	that	that	that	N	O
expected	VBD	expected	expected	expect	N	O
for	IN	for	for	for	N	O
normal	JJ	normal	normal	normal	N	O
growth	NN	growth	growth	growth	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
7	CD	7	7	7	N	O
:	:	:	:	:	N	O
Change	NN	change	change	chang	N	O
in	IN	in	in	in	N	O
Body	NNP	body	body	bodi	N	O
Weight	NNP	weight	weight	weight	Y	O
in	IN	in	in	in	N	O
Pediatric	NNP	pediatric	pediatric	pediatr	N	O
Subjects	NNP	subjects	subject	subject	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O

N	NNP	n	n	n	N	O
Number	NNP	number	number	number	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
assessments	NNS	assessments	assessment	assess	N	O
at	IN	at	at	at	N	O
both	DT	both	both	both	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
Endpoint	NNP	endpoint	endpoint	endpoint	N	O
.	.	.	.	.	N	O

Bipolar	JJ	bipolar	bipolar	bipolar	N	O

I	PRP	i	i	i	N	O
Disorder	NNP	disorder	disorder	disord	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
SAPHRIS2	NNP	saphris2	saphris2	saphris2	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
mgtwice	JJ	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O
SAPHRIS5	NNP	saphris5	saphris5	saphris5	N	O
mgtwice	NN	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O
SAPHRIS10	NNP	saphris10	saphris10	saphris10	N	O
mgtwice	NN	mgtwice	mgtwice	mgtwice	N	O
daily	RB	daily	daily	daili	N	O

Change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
(	(	(	(	(	N	O
kg	NN	kg	kg	kg	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
)	)	)	)	)	N	O
0.5	CD	0.5	0.5	0.5	N	O
(	(	(	(	(	N	O
89	CD	89	89	89	N	O
)	)	)	)	)	N	O
1.7	CD	1.7	1.7	1.7	N	O
(	(	(	(	(	N	O
92	CD	92	92	92	N	O
)	)	)	)	)	N	O
1.6	CD	1.6	1.6	1.6	N	O
(	(	(	(	(	N	O
90	CD	90	90	90	N	O
)	)	)	)	)	N	O
1.4	CD	1.4	1.4	1.4	N	O
(	(	(	(	(	N	O
87	CD	87	87	87	N	O
)	)	)	)	)	N	O

Proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
Subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
7%	CD	7%	7%	7%	N	B-Severity
Increase	NNP	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Body	NNP	body	body	bodi	N	I-AdverseReaction
Weight	NNP	weight	weight	weight	Y	I-AdverseReaction

with	IN	with	with	with	N	O
7%	CD	7%	7%	7%	N	B-Severity
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
weight	VBD	weight	weight	weight	Y	I-AdverseReaction
1.1%	CD	1.1%	1.1%	1.1%	N	O
12.0%	CD	12.0%	12.0%	12.0%	N	O
8.9%	CD	8.9%	8.9%	8.9%	N	O
8.0%	CD	8.0%	8.0%	8.0%	N	O

5.6	CD	5.6	5.6	5.6	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
several	JJ	several	several	sever	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
included	VBD	included	included	includ	N	O
:	:	:	:	:	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
tachycardia	NN	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
,	,	,	,	,	N	O
swollen	JJ	swollen	swollen	swollen	N	B-AdverseReaction
tongue	NN	tongue	tongue	tongu	N	I-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
wheezing	VBG	wheezing	wheezing	wheez	Y	B-AdverseReaction
and	CC	and	and	and	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Orthostatic	JJ	orthostatic	orthostatic	orthostat	N	O
Hypotension	NNP	hypotension	hypotension	hypotens	Y	O
,	,	,	,	,	N	O
Syncope	NNP	syncope	syncope	syncop	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Other	JJ	other	other	other	N	O
Hemodynamic	NNP	hemodynamic	hemodynamic	hemodynam	N	O
Effects	NNS	effects	effect	effect	N	O

SAPHRIS	NNP	saphris	saphris	saphri	N	O
may	MD	may	may	may	N	B-Factor
induce	VB	induce	induce	induc	N	O
orthostatic	JJ	orthostatic	orthostatic	orthostat	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
and	CC	and	and	and	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
early	JJ	early	early	earli	N	O
in	IN	in	in	in	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
its	PRP$	its	it	it	N	O
alpha1	JJ	alpha1	alpha1	alpha1	N	O
-	:	-	-	-	N	O
adrenergic	JJ	adrenergic	adrenergic	adrenerg	N	O
antagonist	NN	antagonist	antagonist	antagonist	N	O
activity	NN	activity	activity	activ	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
adult	NN	adult	adult	adult	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
572	CD	572	572	572	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
doses	NNS	doses	dos	dose	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
378	CD	378	378	378	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
adult	NN	adult	adult	adult	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
379	CD	379	379	379	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
doses	NNS	doses	dos	dose	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0%	CD	0%	0%	0%	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
203	CD	203	203	203	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
adult	NN	adult	adult	adult	N	O
pre	SYM	pre	pre	pre	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
trials	NNS	trials	trial	trial	N	O
without	IN	without	without	without	N	O
comparison	NN	comparison	comparison	comparison	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
1953	CD	1953	1953	1953	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
104	CD	104	104	104	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
1%	CD	1%	1%	1%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
99	CD	99	99	99	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
0%	CD	0%	0%	0%	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
99	CD	99	99	99	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0%	CD	0%	0%	0%	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
101	CD	101	101	101	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
instructed	VBN	instructed	instructed	instruct	N	O
about	IN	about	about	about	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
pharmacologic	JJ	pharmacologic	pharmacologic	pharmacolog	N	O
interventions	NNS	interventions	intervention	intervent	N	O
that	WDT	that	that	that	N	O
help	VBP	help	help	help	N	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
orthostatic	JJ	orthostatic	orthostatic	orthostat	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
sitting	VBG	sitting	sitting	sit	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
edge	NN	edge	edge	edg	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
bed	NN	bed	bed	bed	N	O
for	IN	for	for	for	N	O
several	JJ	several	several	sever	N	O
minutes	NNS	minutes	minute	minut	N	O
before	IN	before	before	befor	N	O
attempting	VBG	attempting	attempting	attempt	N	O
to	TO	to	to	to	N	O
stand	VB	stand	stand	stand	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
morning	NN	morning	morning	morn	N	O
and	CC	and	and	and	N	O
slowly	RB	slowly	slowly	slowli	N	O
rising	VBG	rising	rising	rise	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
seated	JJ	seated	seated	seat	N	O
position	NN	position	position	posit	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

SAPHRIS	NNP	saphris	saphris	saphri	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
known	JJ	known	known	known	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
disease	NN	disease	disease	diseas	N	O
(	(	(	(	(	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	O
infarction	NN	infarction	infarction	infarct	Y	O
or	CC	or	or	or	N	O
ischemic	JJ	ischemic	ischemic	ischem	N	O
heart	NN	heart	heart	heart	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
or	CC	or	or	or	N	O
conduction	NN	conduction	conduction	conduct	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
conditions	NNS	conditions	condition	condit	N	O
which	WDT	which	which	which	N	O
would	MD	would	would	would	N	O
predispose	VB	predispose	predispose	predispos	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
(	(	(	(	(	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	O
,	,	,	,	,	N	O
hypovolemia	NN	hypovolemia	hypovolemia	hypovolemia	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
antihypertensive	JJ	antihypertensive	antihypertensive	antihypertens	N	O
medications	NNS	medications	medication	medic	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
.	.	.	.	.	N	O

SAPHRIS	NNP	saphris	saphris	saphri	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
cautiously	RB	cautiously	cautiously	cautious	N	O
when	WRB	when	when	when	N	O
treating	VBG	treating	treating	treat	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
receive	VBP	receive	receive	receiv	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
can	MD	can	can	can	N	O
induce	VB	induce	induce	induc	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
,	,	,	,	,	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
,	,	,	,	,	N	O
respiratory	NN	respiratory	respiratory	respiratori	N	O
or	CC	or	or	or	N	O
central	JJ	central	central	central	N	O
nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
depression	NN	depression	depression	depress	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
orthostatic	JJ	orthostatic	orthostatic	orthostat	N	O
vital	JJ	vital	vital	vital	N	O
signs	NNS	signs	sign	sign	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
such	JJ	such	such	such	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
if	IN	if	if	if	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
occurs	VBZ	occurs	occurs	occur	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Leukopenia	NNP	leukopenia	leukopenia	leukopenia	Y	O
,	,	,	,	,	N	O
Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Agranulocytosis	NNP	agranulocytosis	agranulocytosis	agranulocytosi	Y	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
and	CC	and	and	and	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
experience	NN	experience	experience	experi	N	O
,	,	,	,	,	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
temporally	RB	temporally	temporally	tempor	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
agents	NNS	agents	agent	agent	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
.	.	.	.	.	N	O

Agranulocytosis	NNP	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
cases	NNS	cases	case	case	N	O
)	)	)	)	)	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	B-DrugClass
agents	NNS	agents	agent	agent	N	I-DrugClass
in	IN	in	in	in	N	I-DrugClass
the	DT	the	the	the	N	I-DrugClass
class	NN	class	class	class	N	I-DrugClass
.	.	.	.	.	N	O

Possible	JJ	possible	possible	possibl	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
include	VBP	include	include	includ	N	O
pre	JJ	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
low	JJ	low	low	low	N	O
white	JJ	white	white	white	N	O
blood	NN	blood	blood	blood	N	O
cell	NN	cell	cell	cell	N	O
count	NN	count	count	count	N	O
(	(	(	(	(	N	O
WBC	NNP	wbc	wbc	wbc	Y	O
)	)	)	)	)	N	O
absolute	VBP	absolute	absolute	absolut	N	O
neutrophil	JJ	neutrophil	neutrophil	neutrophil	N	O
count	NN	count	count	count	N	O
(	(	(	(	(	N	O
ANC	NNP	anc	anc	anc	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
drug	NN	drug	drug	drug	N	O
induced	VBN	induced	induced	induc	N	O
leukopenia	JJ	leukopenia	leukopenia	leukopenia	Y	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
low	JJ	low	low	low	N	O
WBC	NNP	wbc	wbc	wbc	Y	O
ANC	NNP	anc	anc	anc	N	O
or	CC	or	or	or	N	O
drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
induced	VBN	induced	induced	induc	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
,	,	,	,	,	N	O
perform	VB	perform	perform	perform	N	O
a	DT	a	a	a	N	O
complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
count	NN	count	count	count	N	O
(	(	(	(	(	N	O
CBC	NNP	cbc	cbc	cbc	Y	O
)	)	)	)	)	N	O
frequently	RB	frequently	frequently	frequent	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
few	JJ	few	few	few	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
such	JJ	such	such	such	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
sign	NN	sign	sign	sign	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
decline	NN	decline	decline	declin	N	O
in	IN	in	in	in	N	O
WBC	NNP	wbc	wbc	wbc	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
absence	NN	absence	absence	absenc	N	O
of	IN	of	of	of	N	O
other	JJ	other	other	other	N	O
causative	JJ	causative	causative	caus	N	O
factors	NNS	factors	factor	factor	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
for	IN	for	for	for	N	O
fever	NN	fever	fever	fever	Y	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
or	CC	or	or	or	N	O
signs	NNS	signs	sign	sign	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
promptly	RB	promptly	promptly	promptli	N	O
if	IN	if	if	if	N	O
such	JJ	such	such	such	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
or	CC	or	or	or	N	O
signs	NNS	signs	sign	sign	N	O
occur	VBP	occur	occur	occur	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
(	(	(	(	(	N	O
absolute	JJ	absolute	absolute	absolut	N	O
neutrophil	NN	neutrophil	neutrophil	neutrophil	N	O
count	NN	count	count	count	N	O
1000	CD	1000	1000	1000	N	O
mm	NN	mm	mm	mm	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
follow	VB	follow	follow	follow	N	O
their	PRP$	their	their	their	N	O
WBC	NNP	wbc	wbc	wbc	Y	O
until	IN	until	until	until	N	O
recovery	NN	recovery	recovery	recoveri	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
QT	NNP	qt	qt	qt	N	O
Prolongation	NN	prolongation	prolongation	prolong	N	O

The	DT	the	the	the	N	O
effects	NNS	effects	effect	effect	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
interval	NN	interval	interval	interv	N	O
were	VBD	were	were	were	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
dedicated	JJ	dedicated	dedicated	dedic	N	O
adult	NN	adult	adult	adult	N	O
QT	NNP	qt	qt	qt	N	O
study	NN	study	study	studi	N	O
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
trial	NN	trial	trial	trial	N	O
involved	VBD	involved	involved	involv	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
5	CD	5	5	5	N	O
mg	NNS	mg	mg	mg	N	O
,	,	,	,	,	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
15	CD	15	15	15	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
20	CD	20	20	20	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
was	VBD	was	wa	wa	N	O
conducted	VBN	conducted	conducted	conduct	N	O
in	IN	in	in	in	N	O
151	CD	151	151	151	N	O
clinically	RB	clinically	clinically	clinic	N	O
stable	JJ	stable	stable	stabl	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
electrocardiographic	JJ	electrocardiographic	electrocardiographic	electrocardiograph	N	O
assessments	NNS	assessments	assessment	assess	N	O
throughout	IN	throughout	throughout	throughout	N	O
the	DT	the	the	the	N	O
dosing	NN	dosing	dosing	dose	N	O
interval	NN	interval	interval	interv	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
steady	JJ	steady	steady	steadi	N	O
state	NN	state	state	state	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
these	DT	these	these	these	N	O
doses	NNS	doses	dos	dose	N	O
,	,	,	,	,	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
QTc	NNP	qtc	qtc	qtc	Y	I-AdverseReaction
interval	NN	interval	interval	interv	N	I-AdverseReaction
ranging	VBG	ranging	ranging	rang	N	O
from	IN	from	from	from	N	O
2	CD	2	2	2	N	B-Severity
to	TO	to	to	to	N	I-Severity
5	CD	5	5	5	N	I-Severity
msec	NNS	msec	msec	msec	N	I-Severity
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	B-Negation
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
experienced	VBD	experienced	experienced	experienc	N	O
QTc	NNP	qtc	qtc	qtc	Y	B-AdverseReaction
increases	VBZ	increases	increase	increas	N	I-AdverseReaction
60	CD	60	60	60	N	B-Severity
msec	NN	msec	msec	msec	N	I-Severity
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
measurements	NNS	measurements	measurement	measur	N	O
,	,	,	,	,	N	O
nor	CC	nor	nor	nor	N	B-Negation
did	VBD	did	did	did	N	O
any	DT	any	any	ani	N	O
patient	NN	patient	patient	patient	N	O
experience	NN	experience	experience	experi	N	O
a	DT	a	a	a	N	O
QTc	NNP	qtc	qtc	qtc	Y	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
500	CD	500	500	500	N	I-AdverseReaction
msec	NN	msec	msec	msec	N	I-AdverseReaction
.	.	.	.	.	N	O

Electrocardiogram	NNP	electrocardiogram	electrocardiogram	electrocardiogram	Y	O
(	(	(	(	(	N	O
ECG	NNP	ecg	ecg	ecg	Y	O
)	)	)	)	)	N	O
measurements	NNS	measurements	measurement	measur	N	O
were	VBD	were	were	were	N	O
taken	VBN	taken	taken	taken	N	O
at	IN	at	at	at	N	O
various	JJ	various	various	variou	N	O
time	NN	time	time	time	N	O
points	NNS	points	point	point	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
program	NN	program	program	program	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	JJ	daily	daily	daili	N	O
doses	NNS	doses	dos	dose	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Post	NNP	post	post	post	N	O
-	:	-	-	-	N	O
baseline	NN	baseline	baseline	baselin	N	O
QT	NNP	qt	qt	qt	N	B-AdverseReaction
prolongations	NNS	prolongations	prolongation	prolong	N	I-AdverseReaction
exceeding	VBG	exceeding	exceeding	exceed	N	O
500	CD	500	500	500	N	B-Severity
msec	NN	msec	msec	msec	N	I-Severity
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
at	IN	at	at	at	N	O
comparable	JJ	comparable	comparable	compar	N	O
rates	NNS	rates	rate	rate	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	B-Negation
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
Torsade	NNP	torsade	torsade	torsad	N	B-AdverseReaction
de	FW	de	de	de	N	I-AdverseReaction
Pointes	NNP	pointes	pointes	point	N	I-AdverseReaction
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
delayed	JJ	delayed	delayed	delay	N	B-AdverseReaction
ventricular	JJ	ventricular	ventricular	ventricular	N	I-AdverseReaction
repolarization	NN	repolarization	repolarization	repolar	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
avoided	VBN	avoided	avoided	avoid	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
prolong	VB	prolong	prolong	prolong	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
including	VBG	including	including	includ	N	O
Class	NNP	class	class	class	N	O
1	CD	1	1	1	N	O
A	NNP	a	a	a	N	O
antiarrhythmics	NNS	antiarrhythmics	antiarrhythmic	antiarrhythm	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
quinidine	NN	quinidine	quinidine	quinidin	N	O
,	,	,	,	,	N	O
procainamide	NN	procainamide	procainamide	procainamid	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
Class	$	class	class	class	N	O
3	CD	3	3	3	N	O
antiarrhythmics	NNS	antiarrhythmics	antiarrhythmic	antiarrhythm	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
amiodarone	NN	amiodarone	amiodarone	amiodaron	N	O
,	,	,	,	,	N	O
sotalol	NN	sotalol	sotalol	sotalol	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
medications	NNS	medications	medication	medic	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
ziprasidone	NN	ziprasidone	ziprasidone	ziprasidon	N	O
,	,	,	,	,	N	O
chlorpromazine	NN	chlorpromazine	chlorpromazine	chlorpromazin	N	O
,	,	,	,	,	N	O
thioridazine	NN	thioridazine	thioridazine	thioridazin	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
antibiotics	NNS	antibiotics	antibiotic	antibiot	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
gatifloxacin	NN	gatifloxacin	gatifloxacin	gatifloxacin	N	O
,	,	,	,	,	N	O
moxifloxacin	NN	moxifloxacin	moxifloxacin	moxifloxacin	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

SAPHRIS	NNP	saphris	saphris	saphri	N	O
should	MD	should	should	should	N	O
also	RB	also	also	also	N	O
be	VB	be	be	be	N	O
avoided	VBN	avoided	avoided	avoid	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
arrhythmias	NN	arrhythmias	arrhythmia	arrhythmia	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
circumstances	NNS	circumstances	circumstance	circumst	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
torsade	NN	torsade	torsade	torsad	N	O
de	FW	de	de	de	N	O
pointes	NNS	pointes	pointes	point	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
sudden	JJ	sudden	sudden	sudden	N	O
death	NN	death	death	death	Y	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
prolong	VBP	prolong	prolong	prolong	N	O
the	DT	the	the	the	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
interval	NN	interval	interval	interv	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
;	:	;	;	;	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	O
or	CC	or	or	or	N	O
hypomagnesemia	NN	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	O
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
congenital	JJ	congenital	congenital	congenit	N	O
prolongation	NN	prolongation	prolongation	prolong	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Hyperprolactinemia	NN	hyperprolactinemia	hyperprolactinemia	hyperprolactinemia	Y	O

Like	IN	like	like	like	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
that	IN	that	that	that	N	O
antagonize	VBP	antagonize	antagonize	antagon	N	O
dopamine	JJ	dopamine	dopamine	dopamin	N	O
D2receptors	NNS	d2receptors	d2receptors	d2receptor	N	O
,	,	,	,	,	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
can	MD	can	can	can	N	B-Factor
elevate	VB	elevate	elevate	elev	N	B-AdverseReaction
prolactin	NN	prolactin	prolactin	prolactin	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
elevation	NN	elevation	elevation	elev	N	O
can	MD	can	can	can	N	O
persist	VB	persist	persist	persist	N	O
during	IN	during	during	dure	N	O
chronic	JJ	chronic	chronic	chronic	N	O
administration	NN	administration	administration	administr	N	O
.	.	.	.	.	N	O

Hyperprolactinemia	NNP	hyperprolactinemia	hyperprolactinemia	hyperprolactinemia	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
suppress	VB	suppress	suppress	suppress	N	B-AdverseReaction
hypothalamic	JJ	hypothalamic	hypothalamic	hypothalam	N	I-AdverseReaction
GnRH	NNP	gnrh	gnrh	gnrh	N	I-AdverseReaction
,	,	,	,	,	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
reduced	JJ	reduced	reduced	reduc	N	B-AdverseReaction
pituitary	JJ	pituitary	pituitary	pituitari	N	I-AdverseReaction
gonadotropin	NN	gonadotropin	gonadotropin	gonadotropin	N	I-AdverseReaction
secretion	NN	secretion	secretion	secret	N	I-AdverseReaction
.	.	.	.	.	N	O

This	DT	this	this	thi	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
turn	NN	turn	turn	turn	N	O
,	,	,	,	,	N	O
may	MD	may	may	may	N	B-Factor
inhibit	VB	inhibit	inhibit	inhibit	N	B-AdverseReaction
reproductive	JJ	reproductive	reproductive	reproduct	N	I-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
by	IN	by	by	by	N	O
impairing	VBG	impairing	impairing	impair	N	B-AdverseReaction
gonadal	JJ	gonadal	gonadal	gonad	N	I-AdverseReaction
steroidogenesis	NN	steroidogenesis	steroidogenesis	steroidogenesi	N	I-AdverseReaction
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
female	JJ	female	female	femal	N	O
and	CC	and	and	and	N	O
male	JJ	male	male	male	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Galactorrhea	NNP	galactorrhea	galactorrhea	galactorrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
amenorrhea	NN	amenorrhea	amenorrhea	amenorrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
gynecomastia	NN	gynecomastia	gynecomastia	gynecomastia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
impotence	NN	impotence	impotence	impot	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
prolactin	JJ	prolactin	prolactin	prolactin	Y	B-DrugClass
-	:	-	-	-	N	I-DrugClass
elevating	VBG	elevating	elevating	elev	N	I-DrugClass
compounds	NNS	compounds	compound	compound	N	I-DrugClass
.	.	.	.	.	N	O

Long	NNP	long	long	long	N	O
-	:	-	-	-	N	O
standing	NN	standing	standing	stand	N	O
hyperprolactinemia	NN	hyperprolactinemia	hyperprolactinemia	hyperprolactinemia	Y	B-AdverseReaction
when	WRB	when	when	when	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
hypogonadism	NN	hypogonadism	hypogonadism	hypogonad	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
decreased	JJ	decreased	decreased	decreas	N	B-AdverseReaction
bone	NN	bone	bone	bone	N	I-AdverseReaction
density	NN	density	density	densiti	N	I-AdverseReaction
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
female	JJ	female	female	femal	N	O
and	CC	and	and	and	N	O
male	JJ	male	male	male	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
adult	NN	adult	adult	adult	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidences	NNS	incidences	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
prolactin	NN	prolactin	prolactin	prolactin	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
were	VBD	were	were	were	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
versus	NN	versus	versus	versu	N	O
0%	CD	0%	0%	0%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
prolactin	NN	prolactin	prolactin	prolactin	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
were	VBD	were	were	were	N	O
0%	CD	0%	0%	0%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
treatment	NN	treatment	treatment	treatment	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
2%	CD	2%	2%	2%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
treatment	NN	treatment	treatment	treatment	N	O
group	NN	group	group	group	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
treatment	NN	treatment	treatment	treatment	N	O
group	NN	group	group	group	N	O
versus	NN	versus	versus	versu	N	O
to	TO	to	to	to	N	O
1%	CD	1%	1%	1%	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Tissue	NN	tissue	tissue	tissu	N	O
culture	NN	culture	culture	cultur	Y	O
experiments	NNS	experiments	experiment	experi	N	O
indicate	VBP	indicate	indicate	indic	N	O
that	IN	that	that	that	N	O
approximately	RB	approximately	approximately	approxim	N	O
one	CD	one	one	one	N	O
-	:	-	-	-	N	O
third	NN	third	third	third	N	O
of	IN	of	of	of	N	O
human	JJ	human	human	human	N	O
breast	NN	breast	breast	breast	N	O
cancers	NNS	cancers	cancer	cancer	N	O
are	VBP	are	are	are	N	O
prolactin	JJ	prolactin	prolactin	prolactin	Y	O
-	:	-	-	-	N	O
dependent	NN	dependent	dependent	depend	N	O
in	IN	in	in	in	N	O
vitro	NN	vitro	vitro	vitro	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
factor	NN	factor	factor	factor	N	O
of	IN	of	of	of	N	O
potential	JJ	potential	potential	potenti	N	O
importance	NN	importance	importance	import	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
prescription	NN	prescription	prescription	prescript	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
drugs	NNS	drugs	drug	drug	N	O
is	VBZ	is	is	is	N	O
considered	VBN	considered	considered	consid	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
with	IN	with	with	with	N	O
previously	RB	previously	previously	previous	N	O
-	:	-	-	-	N	O
detected	VBN	detected	detected	detect	N	O
breast	NN	breast	breast	breast	N	O
cancer	NN	cancer	cancer	cancer	Y	O
.	.	.	.	.	N	O

Neither	DT	neither	neither	neither	N	B-Negation
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
nor	CC	nor	nor	nor	N	I-Negation
epidemiologic	JJ	epidemiologic	epidemiologic	epidemiolog	N	O
studies	NNS	studies	study	studi	N	O
conducted	VBN	conducted	conducted	conduct	N	O
to	TO	to	to	to	N	O
date	NN	date	date	date	N	O
have	VB	have	have	have	N	O
shown	VBN	shown	shown	shown	N	O
an	DT	an	an	an	N	O
association	NN	association	association	associ	N	O
between	IN	between	between	between	N	O
chronic	JJ	chronic	chronic	chronic	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
this	DT	this	this	thi	N	O
class	NN	class	class	class	N	O
of	IN	of	of	of	N	O
drugs	NNS	drugs	drug	drug	N	O
and	CC	and	and	and	N	O
tumorigenesis	NN	tumorigenesis	tumorigenesis	tumorigenesi	N	B-AdverseReaction
in	IN	in	in	in	N	O
humans	NNS	humans	human	human	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
the	DT	the	the	the	N	O
available	JJ	available	available	avail	N	O
evidence	NN	evidence	evidence	evid	N	O
is	VBZ	is	is	is	N	O
too	RB	too	too	too	N	O
limited	JJ	limited	limited	limit	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
conclusive	JJ	conclusive	conclusive	conclus	N	O
.	.	.	.	.	N	O

5.11	CD	5.11	5.11	5.11	N	O
Seizures	NNS	seizures	seizure	seizur	Y	O

Seizures	NNS	seizures	seizure	seizur	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0%	CD	0%	0%	0%	N	O
and	CC	and	and	and	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
572	CD	572	572	572	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
379	CD	379	379	379	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
adult	NN	adult	adult	adult	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
5	CD	5	5	5	N	O
mg	NNS	mg	mg	mg	N	O
and	CC	and	and	and	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0%	CD	0%	0%	0%	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
503	CD	503	503	503	N	O
,	,	,	,	,	N	O
0	CD	0	0	0	N	O
203	CD	203	203	203	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
and	CC	and	and	and	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
adult	NN	adult	adult	adult	N	O
pre	SYM	pre	pre	pre	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
trials	NNS	trials	trial	trial	N	O
without	IN	without	without	without	N	O
comparison	NN	comparison	comparison	comparison	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
seizures	NNS	seizures	seizure	seizur	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
1953	CD	1953	1953	1953	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	B-Negation
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
seizures	NNS	seizures	seizure	seizur	Y	B-AdverseReaction
in	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

As	IN	as	a	as	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	O
drugs	NNS	drugs	drug	drug	N	O
,	,	,	,	,	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
seizures	NNS	seizures	seizure	seizur	Y	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
potentially	RB	potentially	potentially	potenti	N	O
lower	JJR	lower	lower	lower	N	O
the	DT	the	the	the	N	O
seizure	NN	seizure	seizure	seizur	Y	O
threshold	NN	threshold	threshold	threshold	N	O
.	.	.	.	.	N	O

Conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
lower	VBP	lower	lower	lower	N	O
the	DT	the	the	the	N	O
seizure	NN	seizure	seizure	seizur	Y	O
threshold	NN	threshold	threshold	threshold	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
more	JJR	more	more	more	N	O
prevalent	JJ	prevalent	prevalent	preval	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
or	CC	or	or	or	N	O
older	JJR	older	older	older	N	O
.	.	.	.	.	N	O

5.12	CD	5.12	5.12	5.12	N	O
Potential	NNP	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
Cognitive	NNP	cognitive	cognitive	cognit	N	O
and	CC	and	and	and	N	O
Motor	NNP	motor	motor	motor	N	O
Impairment	NNP	impairment	impairment	impair	N	O

Somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
was	VBD	was	wa	wa	N	O
usually	RB	usually	usually	usual	N	O
transient	JJ	transient	transient	transient	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
highest	JJS	highest	highest	highest	N	O
incidence	NN	incidence	incidence	incid	N	O
reported	VBD	reported	reported	report	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
week	NN	week	week	week	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
adult	NN	adult	adult	adult	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
15%	CD	15%	15%	15%	N	O
(	(	(	(	(	N	O
41	CD	41	41	41	N	O
274	CD	274	274	274	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
13%	CD	13%	13%	13%	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
208	CD	208	208	208	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
7%	CD	7%	7%	7%	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
378	CD	378	378	378	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
adult	NN	adult	adult	adult	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
doses	NNS	doses	dos	dose	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
-	:	-	-	-	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
24%	CD	24%	24%	24%	N	O
(	(	(	(	(	N	O
90	CD	90	90	90	N	O
379	CD	379	379	379	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
6%	CD	6%	6%	6%	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
203	CD	203	203	203	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
adult	NN	adult	adult	adult	N	O
pre	SYM	pre	pre	pre	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
trials	NNS	trials	trial	trial	N	O
without	IN	without	without	without	N	O
comparison	NN	comparison	comparison	comparison	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
18%	CD	18%	18%	18%	N	O
(	(	(	(	(	N	O
358	CD	358	358	358	N	O
1953	CD	1953	1953	1953	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
.	.	.	.	.	N	O

Somnolence	NNP	somnolence	somnolence	somnol	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
)	)	)	)	)	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
(	(	(	(	(	N	O
12	CD	12	12	12	N	O
1953	CD	1953	1953	1953	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
I	PRP	i	i	i	N	O
pediatric	VBP	pediatric	pediatric	pediatr	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
sedation	NN	sedation	sedation	sedat	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hypersomnia	NN	hypersomnia	hypersomnia	hypersomnia	Y	B-AdverseReaction
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
was	VBD	was	wa	wa	N	O
12%	CD	12%	12%	12%	N	O
(	(	(	(	(	N	O
12	CD	12	12	12	N	O
101	CD	101	101	101	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
46%	CD	46%	46%	46%	N	O
(	(	(	(	(	N	O
48	CD	48	48	48	N	O
104	CD	104	104	104	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
53%	CD	53%	53%	53%	N	O
(	(	(	(	(	N	O
52	CD	52	52	52	N	O
99	CD	99	99	99	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
49%	CD	49%	49%	49%	N	O
(	(	(	(	(	N	O
49	CD	49	49	49	N	O
99	CD	99	99	99	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
0%	CD	0%	0%	0%	N	O
,	,	,	,	,	N	O
3%	CD	3%	3%	3%	N	O
,	,	,	,	,	N	O
1%	CD	1%	1%	1%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
2.5	CD	2.5	2.5	2.5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
5	CD	5	5	5	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
cautioned	VBN	cautioned	cautioned	caution	N	O
about	IN	about	about	about	N	O
performing	VBG	performing	performing	perform	N	O
activities	NNS	activities	activity	activ	N	O
requiring	VBG	requiring	requiring	requir	N	O
mental	JJ	mental	mental	mental	N	O
alertness	NN	alertness	alertness	alert	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
operating	VBG	operating	operating	oper	N	O
hazardous	JJ	hazardous	hazardous	hazard	N	O
machinery	NN	machinery	machinery	machineri	N	O
or	CC	or	or	or	N	O
operating	VBG	operating	operating	oper	N	O
a	DT	a	a	a	N	O
motor	NN	motor	motor	motor	N	O
vehicle	NN	vehicle	vehicle	vehicl	N	O
,	,	,	,	,	N	O
until	IN	until	until	until	N	O
they	PRP	they	they	they	N	O
are	VBP	are	are	are	N	O
reasonably	RB	reasonably	reasonably	reason	N	O
certain	JJ	certain	certain	certain	N	O
that	IN	that	that	that	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
therapy	NN	therapy	therapy	therapi	N	O
does	VBZ	does	doe	doe	N	O
not	RB	not	not	not	N	O
affect	VB	affect	affect	affect	N	O
them	PRP	them	them	them	N	O
adversely	RB	adversely	adversely	advers	N	O
.	.	.	.	.	N	O

5.13	CD	5.13	5.13	5.13	N	O
Body	NNP	body	body	bodi	N	O
Temperature	NNP	temperature	temperature	temperatur	N	O
Regulation	NNP	regulation	regulation	regul	N	O

Disruption	NN	disruption	disruption	disrupt	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
's	POS	's	's	's	N	I-AdverseReaction
ability	NN	ability	ability	abil	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
reduce	VB	reduce	reduce	reduc	N	I-AdverseReaction
core	NN	core	core	core	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
temperature	NN	temperature	temperature	temperatur	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
attributed	VBN	attributed	attributed	attribut	N	O
to	TO	to	to	to	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	B-DrugClass
agents	NNS	agents	agent	agent	N	I-DrugClass
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
for	IN	for	for	for	N	O
both	DT	both	both	both	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
and	CC	and	and	and	N	O
acute	JJ	acute	acute	acut	N	O
bipolar	NN	bipolar	bipolar	bipolar	N	O
disorder	NN	disorder	disorder	disord	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
suggestive	VBP	suggestive	suggestive	suggest	N	O
of	IN	of	of	of	N	O
body	NN	body	body	bodi	N	B-AdverseReaction
temperature	NN	temperature	temperature	temperatur	N	I-AdverseReaction
increases	NNS	increases	increase	increas	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
low	JJ	low	low	low	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
comparable	JJ	comparable	comparable	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
trials	NNS	trials	trial	trial	N	O
without	IN	without	without	without	N	O
comparison	NN	comparison	comparison	comparison	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
suggestive	VBP	suggestive	suggestive	suggest	N	O
of	IN	of	of	of	N	O
body	NN	body	body	bodi	N	B-AdverseReaction
temperature	NN	temperature	temperature	temperatur	N	I-AdverseReaction
increases	NNS	increases	increase	increas	N	I-AdverseReaction
(	(	(	(	(	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
feeling	VBG	feeling	feeling	feel	N	B-AdverseReaction
hot	JJ	hot	hot	hot	N	I-AdverseReaction
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
1%	CD	1%	1%	1%	N	O
.	.	.	.	.	N	O

Appropriate	NNP	appropriate	appropriate	appropri	N	O
care	NN	care	care	care	N	O
is	VBZ	is	is	is	N	O
advised	VBN	advised	advised	advis	N	O
when	WRB	when	when	when	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
will	MD	will	will	will	N	O
be	VB	be	be	be	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
conditions	NNS	conditions	condition	condit	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
contribute	VB	contribute	contribute	contribut	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
elevation	NN	elevation	elevation	elev	N	O
in	IN	in	in	in	N	O
core	NN	core	core	core	N	O
body	NN	body	body	bodi	N	O
temperature	NN	temperature	temperature	temperatur	N	O
,	,	,	,	,	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
exercising	VBG	exercising	exercising	exercis	N	O
strenuously	RB	strenuously	strenuously	strenuous	N	O
,	,	,	,	,	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
extreme	VB	extreme	extreme	extrem	N	O
heat	NN	heat	heat	heat	N	O
,	,	,	,	,	N	O
receiving	VBG	receiving	receiving	receiv	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medication	NN	medication	medication	medic	N	O
with	IN	with	with	with	N	O
anticholinergic	JJ	anticholinergic	anticholinergic	anticholinerg	N	O
activity	NN	activity	activity	activ	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
being	VBG	being	being	be	N	O
subject	JJ	subject	subject	subject	N	O
to	TO	to	to	to	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	O
.	.	.	.	.	N	O

5.14	CD	5.14	5.14	5.14	N	O
Suicide	NN	suicide	suicide	suicid	Y	O

The	DT	the	the	the	N	O
possibility	NN	possibility	possibility	possibl	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
suicide	JJ	suicide	suicide	suicid	Y	O
attempt	NN	attempt	attempt	attempt	N	O
is	VBZ	is	is	is	N	O
inherent	JJ	inherent	inherent	inher	N	O
in	IN	in	in	in	N	O
psychotic	JJ	psychotic	psychotic	psychot	Y	O
illnesses	NNS	illnesses	illness	ill	N	O
and	CC	and	and	and	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
disorder	NN	disorder	disorder	disord	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
close	JJ	close	close	close	N	O
supervision	NN	supervision	supervision	supervis	N	O
of	IN	of	of	of	N	O
high	JJ	high	high	high	N	O
-	:	-	-	-	N	O
risk	NN	risk	risk	risk	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
accompany	VB	accompany	accompany	accompani	N	O
drug	NN	drug	drug	drug	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Prescriptions	NNS	prescriptions	prescription	prescript	N	O
for	IN	for	for	for	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
written	VBN	written	written	written	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
smallest	JJS	smallest	smallest	smallest	N	O
quantity	NN	quantity	quantity	quantiti	N	O
of	IN	of	of	of	N	O
tablets	NNS	tablets	tablet	tablet	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
good	JJ	good	good	good	N	O
patient	NN	patient	patient	patient	N	O
management	NN	management	management	manag	N	O
in	IN	in	in	in	N	O
order	NN	order	order	order	N	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
overdose	NN	overdose	overdose	overdos	Y	O
.	.	.	.	.	N	O

5.15	CD	5.15	5.15	5.15	N	O
Dysphagia	NNP	dysphagia	dysphagia	dysphagia	Y	O

Esophageal	NNP	esophageal	esophageal	esophag	N	B-AdverseReaction
dysmotility	NN	dysmotility	dysmotility	dysmotil	N	I-AdverseReaction
and	CC	and	and	and	N	O
aspiration	NN	aspiration	aspiration	aspir	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
antipsychotic	JJ	antipsychotic	antipsychotic	antipsychot	N	B-DrugClass
drug	NN	drug	drug	drug	N	I-DrugClass
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

Dysphagia	NNP	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
and	CC	and	and	and	N	O
0%	CD	0%	0%	0%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
572	CD	572	572	572	N	O
,	,	,	,	,	N	O
0	CD	0	0	0	N	O
379	CD	379	379	379	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
doses	NNS	doses	dos	dose	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
-	:	-	-	-	N	O
10	CD	10	10	10	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
as	IN	as	a	as	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0%	CD	0%	0%	0%	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
378	CD	378	378	378	N	O
,	,	,	,	,	N	O
0	CD	0	0	0	N	O
203	CD	203	203	203	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
short	JJ	short	short	short	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
schizophrenia	NN	schizophrenia	schizophrenia	schizophrenia	Y	O
and	CC	and	and	and	N	O
bipolar	JJ	bipolar	bipolar	bipolar	N	O
mania	NN	mania	mania	mania	Y	O
adult	NN	adult	adult	adult	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
adult	NN	adult	adult	adult	N	O
pre	SYM	pre	pre	pre	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
trials	NNS	trials	trial	trial	N	O
without	IN	without	without	without	N	O
comparison	NN	comparison	comparison	comparison	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
1953	CD	1953	1953	1953	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
.	.	.	.	.	N	O

Aspiration	NNP	aspiration	aspiration	aspir	Y	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
common	JJ	common	common	common	N	O
cause	NN	cause	cause	caus	N	O
of	IN	of	of	of	N	O
morbidity	NN	morbidity	morbidity	morbid	N	O
and	CC	and	and	and	N	O
mortality	NN	mortality	mortality	mortal	N	O
in	IN	in	in	in	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
particular	JJ	particular	particular	particular	N	O
those	DT	those	those	those	N	O
with	IN	with	with	with	N	O
advanced	JJ	advanced	advanced	advanc	N	O
Alzheimer	NNP	alzheimer	alzheimer	alzheim	N	O
's	POS	's	's	's	N	O
dementia	NN	dementia	dementia	dementia	Y	O
.	.	.	.	.	N	O

SAPHRIS	NNP	saphris	saphris	saphri	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
indicated	VBN	indicated	indicated	indic	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
dementia	NN	dementia	dementia	dementia	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
psychosis	NN	psychosis	psychosis	psychosi	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
aspiration	NN	aspiration	aspiration	aspir	Y	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
also	RB	also	also	also	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.16	CD	5.16	5.16	5.16	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Illness	NNP	illness	illness	ill	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
experience	NN	experience	experience	experi	N	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
certain	JJ	certain	certain	certain	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
systemic	JJ	systemic	systemic	system	N	O
illnesses	NNS	illnesses	illness	ill	N	O
is	VBZ	is	is	is	N	O
limited	JJ	limited	limited	limit	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

SAPHRIS	NNP	saphris	saphris	saphri	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
recent	JJ	recent	recent	recent	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	O
infarction	NN	infarction	infarction	infarct	Y	O
or	CC	or	or	or	N	O
unstable	JJ	unstable	unstable	unstabl	N	O
heart	NN	heart	heart	heart	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
these	DT	these	these	these	N	O
diagnoses	NNS	diagnoses	diagnosis	diagnos	N	O
were	VBD	were	were	were	N	O
excluded	VBN	excluded	excluded	exclud	N	O
from	IN	from	from	from	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
orthostatic	JJ	orthostatic	orthostatic	orthostat	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
with	IN	with	with	with	N	O
SAPHRIS	NNP	saphris	saphris	saphri	N	O
,	,	,	,	,	N	O
caution	NN	caution	caution	caution	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
patients	NNS	patients	patient	patient	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

